EP3440213A1 - Vecteurs adénoviraux - Google Patents

Vecteurs adénoviraux

Info

Publication number
EP3440213A1
EP3440213A1 EP17723271.7A EP17723271A EP3440213A1 EP 3440213 A1 EP3440213 A1 EP 3440213A1 EP 17723271 A EP17723271 A EP 17723271A EP 3440213 A1 EP3440213 A1 EP 3440213A1
Authority
EP
European Patent Office
Prior art keywords
sequence
adenoviral
seq
vector
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP17723271.7A
Other languages
German (de)
English (en)
Inventor
Adrian Francis Stewart
Jun Fu
Anja Ehrhardt
Eric EHRKE-SCHULZ
Wenli Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gene Bridges GmbH
Original Assignee
Gene Bridges GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gene Bridges GmbH filed Critical Gene Bridges GmbH
Priority to EP21202131.5A priority Critical patent/EP3998341A3/fr
Publication of EP3440213A1 publication Critical patent/EP3440213A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Definitions

  • the invention relates to adenoviral vectors, cells for use in generating adenoviral vectors, methods for generating adenoviral vectors, and therapeutic uses of adenoviral vectors in gene therapy, tumour therapy and as vaccines.
  • Ad Adenoviruses
  • ITR inverted terminal repeats
  • adenoviruses have received increasing attention both as human and veterinary pathogens and as emerging therapeutics.
  • pathogens adenoviruses cause a multitude of infections with growing numbers of fatalities.
  • An effective treatment is lacking and lethality in immune-compromised patients amounts to 70%.
  • adenoviruses belong to the currently most promising candidates in the group of advanced-therapy medicinal products (ATMPs), with high potential for the treatment of malignant tumours as oncolytic viruses, as genetic vaccines against infectious diseases, and as gene transfer vectors for gene therapy applications.
  • ATMPs advanced-therapy medicinal products
  • Increasing numbers of novel adenovirus types are being identified and it has become clear that adenoviruses comprise an enormous natural diversity of several hundred entities.
  • adenovirus 5 human adenovirus 5
  • sequence diversity of the many adenovirus types is reflected in differences in their biology (e.g. tropism, infectious cycle, host interaction, persistence, immune evasion) and also in their virulence.
  • HAdV-C5 has served for many clinical tumour and gene therapy applications despite there being evidence that its therapeutic efficacy is strongly limited.
  • Gene therapy is an emerging field where therapeutic nucleic acids are delivered into target cells of interest. Recent success stories include the treatment of rare genetic diseases such as Wiskott- Aldrich syndrome 1 , hemophilia B 2 , and metachromatic leukodystrophy 3 .
  • Adenovirus-based vectors represent the most frequently used vector types worldwide 4,5 for tumour therapy, gene therapeutic approaches, and vaccination studies, largely owing to their robust gene delivery properties and the ability to transduce a broad variety of cell types.
  • First clinical trials utilising recombinant adenovirus for cystic fibrosis were initiated in 1993 6 .
  • Adenoviral vectors gained global attention as a gene therapeutic agent when Gendicine was approved by the Chinese food and drug administration in 2003 for treatment of head and neck cancers 7 .
  • tumour-specific replication competent adenoviruses for oncolytic virotherapy.
  • biologicals such as oncolytic viruses are being evaluated in clinical trials, which are likely to herald a growing repertoire of applications 8 .
  • adenoviral vectors recombinant adenoviral vectors
  • AdVs recombinant adenoviral vectors
  • predefined tissue tropism and pre-existing immunity considerably limit their applications.
  • Limitations of vectors and oncolytic viruses based on HAd5 include cell tropism and pre-existing immunity in the human population against HAd5.
  • HAd5 has a strong liver tropism in mice, as well as in humans when delivered intravenously, which is associated with a high innate immunity toxicity profile and sequestration of virus in the liver.
  • the high seroprevalence of HAd5 in the human population results in induction of robust adaptive immune responses against vectors and oncolytic viruses based on this serotype, which hinder their effectiveness.
  • Immune responses and liver sequestration of such vectors and viruses also mean that high doses are often administered to circumvent these problems, risking liver injury and inflammatory shock syndrome.
  • the present invention addresses the problems of pre-existing immunity and limited cell tropism of existing adenovirus vectors and oncolytic adenoviruses.
  • the inventors have facilitated the development of a vast repertoire of new adenoviral vectors and oncolytic viruses that can be used greatly to expand the range of possible applications, with the potential to improve therapeutic efficacy.
  • the present invention is based on the generation of a novel engineered full-genome, type-specific human adenovirus (HAdV) library made through novel recombineering technologies.
  • HdV human adenovirus
  • This library provides the tools for arbitrary genetic modification of viral genomes and allows the generation of new adenoviral vectors, vaccines and oncolytic viruses, for example with improved efficacy and safety.
  • adenoviral genomes can be high-throughput cloned (HTC) and tagged by using advanced linear-linear homologous recombination (LLHR) and linear-circular homologous recombination (LCHR) techniques 11 ' 12 .
  • Wild-type Ad from clinical isolates including around half of the currently known adenovirus types, were propagated and direct high throughput cloning applied.
  • the integrity of cloned Ad genomes was confirmed by DNA restriction pattern and virus reconstitution, and next-generation sequencing (NGS) and phylogenetic analysis was performed.
  • the recombinant TurboGFP fluorescent / NanoLuc luciferase double reporter-marked AdVs facilitate vector characterisation and in vivo imaging.
  • This new engineered adenoviral library will facilitate broader applications in molecular medicine including gene therapy and vaccination studies, as well as basic virology.
  • the library of cloned genomes provided by the inventors facilitates generation of various vector types, genetic modification, insertion of transgenes, and tagging with reporter genes of adenoviruses of various different serotypes, using the methods disclosed herein. Such a system for straightforward manipulation of adenoviral genomes has been lacking.
  • the library provides for an improved scientific understanding of viral and host factors that determine the type-specific interactions of adenoviruses with their host, e.g. as regards tissue tropism, virus persistence, pathogenesis and virulence, and those factors essential to address potential risks associated with newly evolving adenoviruses.
  • This library can also be used to screen for potential new drug targets for anti-adenoviral therapeutic strategies.
  • the invention provides adenoviral vectors with sequences derived from the newly- cloned adenoviral genomes in the library.
  • Vectors comprising these novel sequences have various advantages of therapeutic potential, including altered cell tropisms relative to HAdV5-based vectors, so facilitating the targeting of different cell types, and/or the avoidance of pre-existing immunity against the HAdV5 serotype.
  • the invention provides an adenoviral vector comprising a sequence derived from an adenoviral genome sequence contained within any one of SEQ ID Nos 1 -32 and/or 141 1 , for example, contained within any one of SEQ ID Nos 1 -15, 17-32 and/or 141 1 or contained within any one of SEQ ID NOs: 1 -3, 5-8, 10-12, 14-15, 17-25 and 27-32 and/or 141 1 , or contained within any one of SEQ ID NOs: 1 -3, 5-8, 10-12, 14-15, 17-25 and 27-32, or a sequence at least 50% identical thereto.
  • the invention provides an adenoviral vector comprising the full adenoviral genome sequence contained within any one of SEQ ID Nos 1 -32 and/or 141 1 , for example, contained within any one of SEQ ID Nos 1 -15 and 17- 32 and/or 141 1 or contained within SEQ ID NOs: 1 -3, 5-8, 10-12, 14-15, 17-25 and 27-32 and/or 141 1 , or contained within any one of SEQ ID NOs: 1 -3, 5-8, 10-12, 14-15, 17-25 and 27-32, or a sequence at least 50% identical thereto.
  • the degree of sequence identity is at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9%.
  • the adenoviral vector lacks the E1 region.
  • the invention provides an adenoviral vector comprising the adenoviral genome sequence contained within any one of the sequences listed in SEQ ID Nos 1 -32 and/or 141 1 , for example, contained within any one of SEQ ID Nos 1 -15 and 17-32 and/or 141 1 , or contained within any one of SEQ ID NOs: 1 -3, 5-8, 10-12, 14-15, 17-25 and 27-32 and/or 141 1 , or a sequence at least 50% identical thereto, that lacks the E1 region.
  • the invention provides an adenoviral vector comprising a sequence selected from SEQ ID NOs: 1 -3, 5-8, 10-12, 14-15, 17-25 and 27-32, or a sequence at least 50% identical thereto, that lacks the E1 region.
  • the degree of sequence identity is at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9%.
  • the adenoviral vector lacks the E1 region and the E3 region.
  • the invention provides an adenoviral vector comprising the adenoviral genome sequence contained within any one of the sequences listed in SEQ ID Nos 1 -32 and/or 141 1 , for example, contained within any one of SEQ ID Nos 1 -15 and 17-32 and/or 141 1 or contained within any one of SEQ ID NOs:1 -8, 10-12, 14-15 and 17-32 and/or 141 1 , or a sequence at least 50% identical thereto, that lacks the E1 region and the E3 region.
  • the invention provides an adenoviral vector comprising a sequence selected from SEQ ID NOs: 1 -8, 10-12, 14-15 and 17-32, or a sequence at least 50% identical thereto, that lacks the E1 region and the E3 region.
  • the degree of sequence identity is at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9%.
  • the adenoviral vector lacks the E3 region.
  • the invention provides an adenoviral vector comprising the adenoviral genome sequence contained within any one of the sequences listed in SEQ ID Nos 1 -32 and/or 141 1 , for example, contained within any one of SEQ ID Nos 1 -15 and 17-32 and/or 141 1 or contained within any one of SEQ ID NOs:1 -3, 5-12, 14-15 and 17-32 and/or 141 1 , or a sequence at least 50% identical thereto, that lacks the E3 region.
  • the invention provides an adenoviral vector comprising a sequence selected from SEQ ID NOs:1 -3, 5-12, 14-15 and 17-32, or a sequence at least 50% identical thereto, that lacks the E3 region.
  • the degree of sequence identity is at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9%.
  • the invention provides a library of adenoviral vectors comprising at least 2 (for example, at least 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, or 33) of the adenovirus genome sequences described in SEQ ID NOs 1 - 32 and 141 1 , for example, of the adenovirus genome sequences described in SEQ ID NOs: 1 -3, 5-8, 10-12, 14-15, 17-25 and 27-32 and/or 141 1 , and/or the other adenoviral vectors described herein.
  • these adenoviral sequences are contained within a plasmid backbone.
  • the invention provides an adenoviral vector comprising the 5' and 3' inverted terminal repeat (ITR) sequences from an adenoviral genome sequence disclosed herein.
  • ITR inverted terminal repeat
  • the 5' and 3' ITR regions are taken from the same adenoviral genome and are present at the 5' end and the 3' end, respectively, of the vector.
  • Such vectors are used in conjunction with an adenovirus helper vector according to the invention.
  • the invention provides an adenoviral vector comprising the 5' ITR sequence contained within any one of the sequences listed in SEQ ID Nos 1 -32 and/or 141 1 , or a sequence at least 80% identical to the 5' ITR sequence, at the 5' end, and comprising the 3' ITR sequence contained within any one of the sequences listed in SEQ ID Nos 1 -32 and/or 141 1 , or a sequence at least 80% identical to the 3' ITR sequence, at the 3' end.
  • the invention provides an adenoviral vector comprising the 5' ITR sequence contained within any one of the sequences listed in SEQ ID Nos 1 - 15 and 17-32 and/or 141 1 or contained within any one of SEQ ID NOs: 1 -13 and 18-32 and/or 141 1 , or a sequence at least 80% identical to the 5' ITR sequence, at the 5' end, and comprising the 3' ITR sequence contained within any one of the sequences listed in SEQ ID Nos 1 -15 and 17-32 and/or 141 1 or contained within any one of SEQ ID NO: 1 -13 and 18-32 and/or 141 1 , or a sequence at least 80% identical to the 3' ITR sequence, at the 3' end.
  • the invention provides an adenoviral vector comprising a sequence selected from the sequences contained within any one of SEQ ID Nos 1 -32 and/or 141 1 at the positions defined in Table 1 column 4 or a sequence at least 80% identical thereto, at the 5' end, and at the positions defined in Table 1 , column 5, or a sequence at least 80% identical thereto, at the 3' end.
  • the invention provides an adenoviral vector comprising a sequence selected from the sequences contained within any one of SEQ ID Nos 1 -15 and 17-32 and/or 141 1 or contained within any one of SEQ ID NO: 1 -13 and 18-32 and/or 141 1 at the positions defined in Table 1 , column 4 or a sequence at least 80% identical thereto, at the 5' end, and at the positions defined in Table 1 , column 5, or a sequence at least 80% identical thereto, at the 3' end.
  • the invention provides an adenoviral vector comprising a sequence selected from SEQ ID NOs:33-45 and 50-64, or a sequence at least 80% identical thereto, at the 5' end, and a sequence selected from SEQ ID NOs:97-109 and 1 14-128, or a sequence at least 80% identical thereto, at the 3' end.
  • adenovirus helper vector comprising a sequence selected from SEQ ID NOs:33-45 and 50-64, or a sequence at least 80% identical thereto, at the 5' end, and a sequence selected from SEQ ID NOs:97-109 and 1 14-128, or a sequence at least 80% identical thereto, at the 3' end.
  • the invention provides an adenoviral vector comprising the sequence provided in Table 3, column 2 (headed "500bp 5' UTR") of an adenovirus selected from B3, B16, C1 , C2, C5, C6, D10, D13, D20, D24, D25, D26, D27, D33, D37, D69 and E4, or a sequence at least 80% identical thereto, at the 5' end, and comprising the sequence provided in Table 3, column 4 (headed "150bp 3' ITR") of an adenovirus selected from B3, B16, C1 , C2, C5, C6, D10, D13, D20, D24, D25, D26, D27, D33, D37, D69 and E4, or a sequence at least 80% identical thereto, at the 3' end.
  • the 5' and 3' sequences are derived from the same adenovirus.
  • the invention provides an adenoviral vector comprising a fiber gene from a genome sequence provided herein.
  • the invention provides an adenoviral vector comprising a fiber gene selected from any one of SEQ ID NOs 129-160 and 1443, for example, any one of SEQ ID NOs 129-160, or a sequence at least 70% identical thereto.
  • the invention provides an adenoviral vector comprising a fiber gene selected from SEQ ID NOs:130- 131 , 135, 138-140, 142, 145-146, 149, 151 , 153, 155 and 158-160, or a sequence at least 70% identical thereto.
  • the adenoviral vector does not contain any regions coding for adenoviral proteins other than these fiber proteins.
  • the invention also provides adenoviral helper vectors with the same features.
  • the vector may further or alternatively comprise a penton gene selected from any one of SEQ ID NOs 161 -192 and 1426, for example, any one of SEQ ID NOs: 161 -192, for example selected from SEQ ID NOs:161 -175 and 177-192, or a sequence at least 70% identical thereto, and/or a hexon gene selected from any one of SEQ ID NOs 193-224 and 1431 , for example, any one of SEQ ID NOs: 193-224, for example, selected from SEQ ID NOs:193-207 and 209-224, or a sequence at least 70% identical thereto.
  • a penton gene selected from any one of SEQ ID NOs 161 -192 and 1426, for example, any one of SEQ ID NOs: 161 -192, for example selected from SEQ ID NOs:161 -175 and 177-192, or a sequence at least 70% identical thereto
  • a hexon gene selected from any one of SEQ ID NOs 193-224
  • adenoviral vectors of the invention may be used as adenoviral vaccine vectors comprising a gene encoding an antigen, for example from human immunodeficiency virus (HIV), Ebolavirus, Zika virus, hepatitis B virus, hepatitis C virus, influenza virus, Mycobacterium tuberculosis, or Plasmodium falciparum.
  • HAV human immunodeficiency virus
  • Ebolavirus Zika virus
  • hepatitis B virus hepatitis C virus
  • influenza virus Mycobacterium tuberculosis
  • Plasmodium falciparum Plasmodium falciparum.
  • the invention also provides an adenoviral helper vector comprising the adenoviral genome sequence contained within any one of SEQ ID NOs:1 -32 and/or 141 1 , for example, contained within any one of SEQ ID NOs: 1 -13 and 18-32 and 141 1 or contained within any one of SEQ ID NOs: 1 -13 and 18-32, or a sequence at least 50% identical thereto, that lacks the E1 region and comprises loxP sites (SEQ ID NO:221 ) or FRT sites (SEQ ID NO:222), wherein the loxP or FRT sites are positioned such that the first is downstream of the part of the sequence corresponding to the 5'ITR and upstream of the packaging signal (Table 1 , column 4), and the second is upstream of the position of the deleted E1 region and downstream of the part of the sequence corresponding to the 5'ITR and packaging signal (Table 1 , column 4).
  • the invention also provides an adenoviral helper vector comprising a sequence selected from SEQ ID NOs:1 -13 and 18-32, or a sequence at least 50% identical thereto, that lacks the E1 region and comprises loxP sites (SEQ ID NO:221 ) or FRT sites (SEQ ID NO:222), wherein the loxP or FRT sites are positioned such that the first is downstream of the part of the sequence corresponding to SEQ ID NOs:65-77 and 82-96, respectively, and the second is upstream of the position of the deleted E1 region and downstream of the part of the sequence corresponding to SEQ ID NOs:33-45 and 50- 64, respectively.
  • the invention also provides a cell encoding, and capable of expressing, an adenoviral E1 region contained within any one of SEQ ID Nos 1 -32 and/or 141 1 , or a sequence at least 70% identical to said E1 region.
  • the invention provides a cell encoding, and capable of expressing, an adenoviral E1 region selected from within any one of SEQ ID NOs: 1 -3, 5-8, 10-12, 14-15, 17-25, 27-32 and 141 1 , for example, selected from SEQ ID NOs: 1 -3, 5-8, 10-12, 14-15, 17- 25 or 27-32, or a sequence at least 70% identical to said E1 region.
  • the cell may further express Cre recombinase or Flp recombinase. Such cells are used for producing adenovirus vectors according to the invention.
  • the invention provides an oncolytic adenoviral vector comprising an E1 region selected from SEQ ID NOs 1 -32 and 141 1 , for example, selected from SEQ ID NOs: 1 -8, 10- 12, 14-15, 18-25, 27-32 or 141 1 , or for example selected from SEQ ID NOs:1 -8, 10-12, 14-15, 18- 25 or 27-32, or a sequence at least 70% identical to said E1 region.
  • the oncolytic vector may further comprise a) an E2 region derived from SEQ ID NOs 1 -32 and 141 1 , for example selected from SEQ ID NOs:1 -8, 10-12, 14-15, 18-25, 27-32 or 141 1 , or for example selected from SEQ ID NOs: 1 -8, 10-12, 14-15, 18-25 or 27-32, or a sequence at least 70% identical to said E2 region;
  • an E4 region derived from SEQ ID NOs 1 -32 and 141 1 for example selected from SEQ ID NOs:1 -8, 10-12, 14-15, 18-25, 27-32 or 141 1 , or for example selected from SEQ ID NOs: 1 -8, 10-12, 14-15, 18-25 or 27-32, or a sequence at least 70% identical to said E4 region;
  • an L1 region derived from SEQ ID NOs 1 -32 and 141 1 for example selected from SEQ ID NOs:1 -8, 10-12, 14-15, 18-25, 27-32 or 141 1 , or for example selected from SEQ ID NOs:1 -8, 10-12, 14-15, 18-25 or 27-32, or a sequence at least 70% identical to said L1 region;
  • an L2 region derived from SEQ ID NOs 1 -32 and 141 1 for example selected from SEQ ID NOs:1 -8, 10-12, 14-15, 18-25, 27-32 or 141 1 , or for example selected from SEQ ID NOs: 1 -8, 10-12, 14-15, 18-25 or 27-32, or a sequence at least 70% identical to said L2 region;
  • an L3 region derived from SEQ ID NOs 1 -32 and 141 1 for example selected from SEQ ID NOs:1 -8, 10-12, 14-15, 18-25, 27-32 or 141 1 , or for example selected from SEQ ID NOs: 1 -8, 10-12, 14-15, 18-25 or 27-32, or a sequence at least 70% identical to said L3 region;
  • an L4 region derived from SEQ ID NOs 1 -32 and 141 1 for example selected from SEQ ID NOs:1 -8, 10-12, 14-15, 18-25, 27-32 or 141 1 , or for example selected from SEQ ID NOs: 1 -8, 10-12, 14-15, 18-25 or 27-32, or a sequence at least 70% identical to said L4 region;
  • an L5 region derived from SEQ ID NOs 1 -32 and 141 1 for example selected from
  • SEQ ID NOs:1 -8, 10-12, 14-15, 18-25, 27-32 or 141 1 or for example selected from SEQ ID NOs: 1 -8, 10-12, 14-15, 18-25 or 27-32, or a sequence at least 70% identical to said L5 region.
  • the E1 and/or E2 region of the oncolytic vector may be mutated or partially deleted to enhance replication activity and/or tumour specificity.
  • these multiple regions may be derived from the same adenovirus genome or from different adenoviral genomes.
  • the oncolytic adenoviral vectors of the invention may further comprise:
  • tumour- or tissue-selective promoter e) a tumour- or tissue-selective promoter
  • the adenoviral vectors of the invention may be used in therapy.
  • the invention also provides a method of treatment comprising administering an adenoviral vector of the invention to a patient.
  • the adenoviral vector comprises a transgene.
  • the invention comprises treating cancer comprising administering an adenoviral vector as described herein that is oncolytic for cells of the cancer.
  • the invention also provides a method of generating an adenoviral vector or helper vector, a cell, or an oncolytic adenoviral vector as defined above.
  • the invention further provides a method of inserting one or more transgenes into an adenoviral vector or helper vector or an oncolytic adenoviral vector according to the invention.
  • the invention also provides an adenoviral genome sequence selected from within any one of SEQ ID NOs 1 -32 and 141 1 , for example, selected from within any one of SEQ ID NOs:1 -3, 5-12, 14-15, 17-32 and 141 1 , or selected from within any one of SEQ ID NOs:1 -3, 5-12, 14-15 and 17-32, comprising one or more reporter genes and means for their expression, replacing part or all of the E3 region.
  • the invention provides an adenoviral sequence selected from SEQ ID NOs:1 -3, 5-12, 14-15 and 17-32, comprising one or more reporter genes and means for their expression, replacing part or all of the E3 region. Vectors comprising such sequences are also provided.
  • the invention also provides a method of screening for anti-adenoviral drugs, comprising:
  • sequence identity means sequence identity determined by the Smith-Waterman homology search algorithm as implemented in MPSRCH program (Oxford Molecular) using an affine gap search with parameters: gap penalty 10, gap extension penalty 0.5.
  • high-capacity adenoviral vector refers to an adenoviral vector that comprises only non-coding adenoviral sequences, and lacks all adenoviral coding regions.
  • First generation adenoviral vector refers to an adenoviral vector lacking the E1 and/or E3 regions.
  • An "adenoviral helper vector” is an adenoviral vector which provides the required early and late proteins necessary for replication, and is used in conjunction with high-capacity or "helper- dependent" vectors to allow their construction and propagation.
  • transgene refers to a gene or genetic material from a heterologous organism or virus.
  • a transgene inserted into an adenoviral vector or oncolytic adenovirus will be a gene that is not derived from that particular adenovirus.
  • the gene may be derived from any other organism or virus.
  • expression cassette in relation to a transgene or antigen refers to the transgene or antigen to be expressed, in conjunction with means for its expression (e.g. a promoter).
  • antigen in the present disclosure refers to an immunogenic protein that is not endogenous to the adenovirus of interest, i.e. it is encoded by a transgene derived from a heterologous organism or virus.
  • immunomodulatory refers to the inhibition or reduction of one or more biological activities of the immune system and includes, but is not limited to, downregulation of immune responses and inflammatory states as well as changes in cytokine profile, cytotoxic activity and antibody production.
  • the term "therapy” or “treatment” refers to treatment of a disease or disease pathology, and includes both therapeutic and prophylactic treatment.
  • the term is not limited to curative treatment and covers any beneficial effect on disease processes (e.g. reducing the risk of, slowing, halting or reversing a disease process).
  • composition comprising X may consist exclusively of X or may include something additional e.g. X + Y.
  • the invention refers to a sequence that has at least X% sequence identity with another sequence
  • the invention further comprises sequences having a higher level of sequence identity with that sequence. For example, if a sequence is said to have at least 50% sequence identity with another sequence, then in alternative embodiments, a sequence having at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, 99.5%, 99.8%, 99.9% is also provided.
  • adenovirus type when referring to the adenovirus type, this may be in the form of the species and number, e.g. adenovirus C5, or simply by "Ad” followed by the number, e.g. Ad5. These terms are used interchangeably and have the same meaning.
  • the adenovirus library generated by the present inventors forms the basis for the generation of new adenovirus vectors, vaccines and oncolytic adenoviruses, as described below.
  • the novel sequences from the newly-cloned adenoviruses confer improved properties on the vectors and oncolytic viruses.
  • SEQ ID NO: 141 1 corresponds to the sequence of the newly-cloned F41 adenovirus genome. Sequence variants of the B1 1 , D8 and D17 adenoviruses are contained within SEQ ID NOs 1413, 1414 and 1415 respectively. It will be understood that any embodiments of the invention related to SEQ ID NOs 9, 18 and 22 may also be extrapolated to encompass SEQ ID NOs 1413, 1414 and 1415 respectively, if required.
  • Sequences of individual transcription units and genes of particular importance from the novel cloned adenoviruses are also provided in the sequence listing.
  • the SEQ ID NOs of these genes are set out in the tables below, together with an indication of the function of relevant genes.
  • Any plasmid sequences contained at the 5' and/or 3'-ends of the genome sequences in SEQ ID Nos 1 -32 and 141 1 would be straightforward for a person skilled in the art to identify, as they would simply identify the ITRs of the adenovirus genomes, which are known in the art, and are known to define the ends of the adenovirus genome.
  • Non-coding regions from the 5' and 3' untranslated regions of the adenoviral genomes are important in generating high-capacity adenoviral vectors of the invention (see below).
  • High-capacity adenoviral vectors comprise 5' and 3' inverted terminal repeats (ITRs), which are included in high-capacity adenoviral vectors. These are found within around 150bp of each end of the viral genome.
  • the 5' region also comprises the packaging signal ( ⁇ ). This ensures that the DNA is packaged into virus particles.
  • the packaging signal is found within 500bp of the 5' end of the genome, downstream of the 5' ITR.
  • the positions of the regions in SEQ IDs 1 -32 and 141 1 which contain the 5'ITR, the 5'ITR and the packaging signal, and the 3'ITR are shown in Table 1 .
  • the sequences comprising the 500bp and 150bp of the 5'-end, and the 150bp of the 3'-end of SEQ IDs 1 -32 are shown in Table 3. Some of these sequences comprise plasmid sequence. However, the 150bp 5'UTR and 150bp 3'ITR SEQ ID NOs corresponding to the B3, B16, C1 , C2, C5, C6, D10, D13, D20, D24, D25, D26, D27, D33, D37, D69 and E4 adenoviruses in Table 3 do comprise the 5'ITRs and the 3'ITRs, respectively as defined in Table 1 . Table 3 - key non-coding regions
  • the late transcription units encode structural proteins, which are responsible for virus tropism.
  • the main structural proteins which form the viral capsid are hexon, penton base, and fiber. Fiber proteins protrude from the capsid surface and are primarily responsible for cell tropism, though other parts of the viral capsid (e.g. penton base) may contribute in some cases 17 .
  • the fiber knob binds to receptors on the surface of certain cells in order to mediate cell attachment and the first step of cell entry. Penton base is involved in internalisation of virus particles via interaction with cellular integrins 13 .
  • the hexon protein contains hypervariable regions (HVRs) which are serotype-specific and are therefore considered to be major immune determinants. Most neutralising antibodies against HAd5 bind to the hexon HVR sequences, and to a lesser extent the fiber knob 14 .
  • HVRs hypervariable regions
  • the capsid proteins are also responsible for the induction of host immune responses such as neutralising antibodies. Antigens at the surface of the virion are mainly type-specific 13 . Accordingly, constructing vectors or oncolytic viruses with one or more capsid proteins listed in Table 4 below may help to avoid the issues of pre-existing immunity encountered with HAdV5-based vectors and viruses, for example if the virus from which the capsid protein is derived has a lower seroprevalence in the human population than HAdV5.
  • SEQ ID NOs 1443, 1426 and 1431 correspond to the fiber, penton and hexon genes of the newly-cloned F41 adenovirus genome, respectively, and the invention similarly encompasses constructing vectors or oncolytic viruses with these sequences.
  • a vector includes the L1 region, this means that it comprises all of the open reading frames (ORFs) forming part of the L1 region, as well as any intervening sequences (coding or non-coding).
  • the vector also includes any flanking sequence involved in expression of the L1 genes (e.g. starting from the upstream transcription start site).
  • ORFs from each of these regions, for each of the cloned viruses, are provided in Table 5.
  • adenoviral vectors and oncolytic adenoviruses currently in use or development are based on HAdV5.
  • HAdV5-based vectors and viruses are the strong liver cell tropism of HAdV5 when administered intravenously.
  • adenoviral genome sequences cloned by the present inventors provide a wide repertoire of sequences from which vectors and oncolytic viruses can be made, and many of these vectors and oncolytic viruses will have the advantage of a different cell tropism from HAdV5, based on the cell tropism of the virus from which the vector or oncolytic virus sequence is derived. If the vector or oncolytic virus is made as a hybrid of sequences from different viruses, its cell tropism will be determined by the tropism of the virus from which the capsid genes are derived (in particular the fiber shaft and knob). For example, human adenovirus type 17 (HAdV17) shows endothelial cell tropism (see Example 3).
  • Species B viruses demonstrate high transduction efficiencies in epithelial (HeLa and A549 cells) and endothelial cells, while Ad5 still displays the highest transduction rates in other human and murine cell types (hepatocytes, lymphocytes, neuroblastoma cells and myoblasts). Exploring natural adenovirus diversity revealed distinct tropisms in vivo (Example 1 ; Figure 2)
  • Table 6 summarises the cell and/or tissue tropism of the cloned adenoviruses, any known cellular receptors for the cloned adenoviruses, and the types of infection caused by these adenoviruses.
  • the tissue tropism and type of infection caused provide some guidance as to the likely cell tropism.
  • Table 6 also lists some possible therapeutic uses of vectors or oncolytic viruses derived from these adenoviral genomes, based on their tropism. Table 6 - tropism
  • B1 1 Epithelial/ CD46 Hematopoietic Gastrointestinal, Epithelial tumours endothelial DSG-2 17 cells, kidney, respiratory, urinary
  • endothelial cells kidney, respiratory, urinary
  • endothelial cells kidney, respiratory, urinary
  • mice including hepatitis
  • hCAR human coxsackievirus and adenovirus receptor
  • DSG-2 desmoglein 2 is a calcium-binding transmembrane glycoprotein and forms part of the cadherin protein family. DSG-2 is a component of the cell-cell adhesion structure in epithelial cells, and is overexpressed in various epithelial cancers, including gastric cancer, squamous cell carcinomas, melanoma, metastatic prostate cancer and bladder cancer 17 .
  • the invention provides a method of infecting a cell with an adenoviral vector according to the invention wherein the cell is an epithelial cell or an endothelial cell. Also provided is a method of infecting a tissue with an adenoviral vector according to the invention wherein the tissue is selected from the intestine, tonsils, respiratory tract, hematopoietic cells, kidney, urinary bladder and eye.
  • the invention provides a method for treating one or more diseases recited in Table 4, for example, wherein the treatment comprises infecting the corresponding cell and/or tissue as recited in Table 4.
  • the invention provides a method of treating epithelial tumours comprising administering an adenoviral vector of the invention.
  • the invention provides a method of treating endothelial disease or dysfunction, for example a coagulation disorder, comprising administering an adenoviral vector of the invention.
  • the invention further provides a method of treating a disease affecting the gastrointestinal, respiratory or urinary tract or the keratoconjunctiva or hepatitis infection comprising administering an adenoviral vector of the invention.
  • the invention provides an oncolytic adenoviral vector, for use in treating osteosarcoma, wherein the oncolytic adenoviral vector is derived from the adenovirus B21.
  • the invention provides a method of treating osteosarcoma or glioblastoma comprising administering an oncolytic adenoviral vector derived from adenovirus B21 (B21 is the same as Ad21 ).
  • the invention provides an oncolytic adenoviral vector, for use in treating lung carcinomas, wherein the oncolytic adenoviral vector is derived from the adenovirus B35 or D69.
  • the invention provides a method of treating a lung carcinoma comprising administering an oncolytic adenoviral vector derived from adenovirus B35 or D69.
  • the invention provides a method of targeting human airway epithelial comprising administering an adenoviral vector derived from adenovirus B21 , D37 or D69.
  • the invention provides an adenoviral vector for use in infecting lung cells or tissue.
  • the adenoviral vector is derived from Ad21 , Ad3, Ad37, or Ad69.
  • the adenoviral viral vector is for use in treating a disease of the lung, such as lung cancer or cystic fibrosis.
  • the invention provides a method of treating a disease of the lung comprising administering an adenoviral vector derived from adenovirus Ad21.
  • the adenoviral vector is oncolytic.
  • the adenoviral vector comprises a transgene capable of treating the disease.
  • the adenoviral vector carries the CRISPR/Cas9 components and the treatment involves correcting the mutated gene sequence.
  • the invention provides a method of transducing osteosarcoma cells or an osteosarcoma-derived cell line, comprising contacting the cells with a plasmid or adenoviral vector of the present invention, preferably wherein adenoviral sequences are derived from the adenovirus B21 .
  • the invention provides a method of transducing epithelial cells or an epithelial-derived cell line, comprising contacting the cells with a plasmid or adenoviral vector of the present invention, preferably wherein adenoviral sequences are derived from the adenovirus B3, B14, B16, B35 or B50.
  • the invention provides a method of transducing endothelial cells or an endothelial-derived cell line, comprising contacting the cells with a plasmid or adenoviral vector of the present invention, preferably wherein adenoviral sequences are derived from the adenovirus B16 or B50.
  • the invention provides a method of transducing breast cancer cells or a breast cancer-derived cell line, comprising contacting the cells with a plasmid or adenoviral vector of the present invention, preferably wherein adenoviral sequences are derived from the adenovirus D37.
  • the invention also provides a method of treating breast cancer comprising administering an adenoviral vector derived from adenovirus D37.
  • the adenoviral vector is oncolytic.
  • the adenoviral vector comprises a transgene capable of treating the disease.
  • the invention provides a method of transducing liver cells or a liver-derived cell line, comprising contacting the cells with a plasmid or adenoviral vector of the present invention, preferably wherein adenoviral sequences are derived from the adenovirus C5, or B50.
  • the invention provides a method of transducing lung cells or a lung-derived cell line, comprising contacting the cells with a plasmid or adenoviral vector of the present invention, preferably wherein adenoviral sequences are derived from the adenovirus Ad21 , Ad37 or Ad69.
  • the invention also provides adenoviral vectors of the invention for use in treating osteosarcoma, preferably wherein adenoviral sequences are derived from the adenovirus B21.
  • the invention provides a method of screening for cell tropisms, which comprises:
  • the invention provides a method of screening for cell tropisms, which comprises:
  • steps a) and b) repeating steps a) and b) for at least one more member of the library (e.g. for at least
  • steps a) to c) optionally repeating steps a) to c) using a different cell type.
  • the vector may comprise a reporter gene which is a fluorescent protein or luciferase
  • step b) may comprise determining whether the cell fluoresces or glows as a result of expression of the fluorescent protein or the luciferase.
  • step b) may comprise adding a luciferase substrate, such as furimazine or luciferin, and measuring the luminescence units.
  • the method of screening for cell tropisms is carried out in vitro. In some embodiments, the method of screening for cell tropisms is carried out in vivo and comprises analysing the biodistribution as detected by transgene expression levels and/or viral genome level. For example, an in vivo method may be carried out in a mouse, rat, rabbit or guinea pig.
  • the invention further provides a method of screening for cell tropisms, which comprises:
  • the invention provides a method of screening for cell tropisms, which comprises: a) contacting a cell with an adenoviral vector from a library of two or more adenoviral vectors as described herein;
  • steps a) and b) repeating steps a) and b) for at least one more member of the library (e.g. for at least
  • steps a) to c) optionally repeating steps a) to c) using a different cell type.
  • the step of determining whether the vector lyses the cells comprises staining the cells with crystal violet or methylene blue.
  • a method of screening for cell tropisms as described herein allows identification of a virus candidate for disease specific targeting. This allows development of novel therapeutic agents by carrying out further steps of modifying the virus using the methods described herein, e.g. so that it contains a transgene. Accordingly, the invention also provides a virus candidate for disease specific targeting identified by or identifiable by the method of screening for cell tropisms as described herein.
  • the invention provides a method of treatment of a disease that affects a cell type comprising administering an adenoviral vector as described herein which has been identified (or can be identified) as infecting that cell type by a method of screening for cell tropisms as described herein, wherein the vector has been modified to incorporate one or more transgenes useful for treating the disease and/or wherein the vector is oncolytic for the cell type.
  • the one or more transgenes comprise a therapeutic agent.
  • the one or more transgenes is the CRISPR/Cas9 system.
  • the invention also provides a method of targeting a cell by contacting the cell with an adenoviral vector as described herein, wherein the type of cell has been identified (or can be identified) as a type of cell that is infected by the adenoviral vector using a method of screening for cell tropisms as described herein.
  • the vector has been modified to incorporate one or more transgenes.
  • the vector is oncolytic for the cell type.
  • the early transcription units are E1 , E2, E3 and E4.
  • E1 , E2 and E4 are majorly involved in the replication cycle of adenoviruses.
  • the E1 transcription unit comprises E1A and E1 B, and is the main unit responsible for initiating replication after cellular infection.
  • E1 A activates transcription of a number of viral genes as well as host cell genes.
  • the protein coding genes of E1 B have various functions, for instance suppressing apoptosis.
  • the E1 region can be deleted in the vectors of the invention to make them replication deficient and consequently safer for use in therapy. Deletion of the E1 region (and optionally also other regions of the viral genome) also provides space to accommodate transgenes.
  • the E2 transcription unit encodes the DNA polymerase (Pol), the terminal protein (TP), and the DNA- binding protein (DBP) which are involved in replication and amplification of adenoviral DNA.
  • Poly DNA polymerase
  • TP terminal protein
  • DBP DNA- binding protein
  • Products of the E4 transcription unit are involved in transcription, apoptosis, cell cycle control, DNA repair, cell signalling and posttranslational modifications.
  • the E3 transcription unit exhibits immunomodulatory functions: it protects cells from killing mediated by cytotoxic T cells and death-inducing cytokines, and can prevent apoptosis. This region varies significantly between the different adenovirus serotypes and can contain a different number of protein-coding genes.
  • Table 7 lists the open reading frames (ORFs) in the each of the early transcription units, for each of the cloned adenoviral genomes.
  • deletion of the E1 region means that minimally all the ORFs listed in Table 7 as forming part of the E1 region are deleted, and preferably also any intervening sequence, e.g. non-coding sequence or any further coding sequence. Some flanking sequence may also be deleted (e.g. the transcription start site).
  • deletion of the E3 region means that minimally all the ORFs listed in Table 7 as forming part of the E3 region are deleted, and preferably also any intervening sequence, e.g. non-coding sequence or any further coding sequence. Some flanking sequence may also be deleted (e.g. the transcription start site).
  • a vector includes the E1 region, this means that it comprises all of the ORFs listed in Table 7 as forming part of the E1 region, including any intervening sequences (coding or non-coding).
  • the vector also includes any flanking sequence involved in expression of the E1 genes (e.g. starting from the upstream transcription start site). Analogous provisions apply to the E2, E3 and E4 regions. Table 7 - ORFs in E1 , E2, E3 and E4 regions
  • Adenoviral vectors may be replication-deficient (RD) or replication-competent (RC). Vectors have certain regions of the adenoviral genome deleted to provide space for foreign DNA (e.g. transgenes). Replication-deficient adenoviral vectors are formed by deletion of the E1 region (which comprises the E1 A and E1 B essential early genes) in the adenoviral genome, which ensures complete inhibition of viral replication in cells. Amplification of replication-deficient adenoviral vectors containing DNA of non-viral origin is feasible if essential viral components are provided in the helper cell in trans. This can be accomplished by generation of stable cell lines which complement for the lacking genes (see below).
  • Replication-competent adenoviral vectors usually lack the E3 region, as the E3 genes are not essential for Ad replication in cell culture or in vivo. Further details regarding RD and RC vectors may be found in reference 25, which is incorporated herein by reference.
  • adenoviral cell and tissue tropism is determined primarily by the fiber capsid protein, in particular the stalk and knob regions of this protein. Other viral capsid proteins may also contribute to cell entry.
  • the invention provides an adenoviral vector comprising a fiber gene selected from SEQ ID NOs:130-131 , 135, 138-140, 142, 145-146, 149, 151 , 153, 155 and 158-160, or a sequence at least 70% identical thereto.
  • the sequence is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to a sequence selected from SEQ ID NOs:130-131 , 135, 138-140, 142, 145-146, 149, 151 , 153, 155 and 158-160.
  • the vector may further comprise a penton gene selected from SEQ ID NOs: 161 -175 and 177-192, or a sequence at least 70% identical thereto.
  • the sequence is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to a sequence selected from SEQ ID NOs: 161 -175 and 177-192.
  • the vector may further comprise a hexon gene selected from SEQ ID NOs: 193-207 and 209-224, or a sequence at least 70% identical thereto.
  • the sequence is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to a sequence selected from SEQ ID NOs: 193-207 and 209-224.
  • the fiber, penton and hexon genes are preferably all derived from the same viral serotype (see Table 4).
  • Hybrid vectors may be constructed, comprising a fiber gene selected from SEQ ID NOs: 130-131 , 135, 138-140, 142, 145-146, 149, 151 , 153, 155 and 158-160 or a sequence at least 70% identical thereto, but comprising further viral sequences (coding and/or non-coding) from a different adenoviral serotype.
  • the further viral sequences are from another adenoviral serotype forming part of the new library disclosed herein (selected from SEQ ID NOs:1 -15 and 17-32), and preferably are not from human adenovirus 5 (Accession No.
  • Adenoviral non-coding and coding sequences that can be incorporated into different types of vectors of the invention are discussed in further detail below.
  • This embodiment of the invention may be combined with any of the viral vector types described herein, including first generation vectors, including vaccine vectors.
  • the vector according to this embodiment may also be a helper vector.
  • the E1 region and/or the E3 region is deleted in first generation vectors of the invention. Deletion of such regions (and optionally also other regions of the viral genome) provides space to accommodate transgenes. Deletion of the E1 region makes the vectors replication deficient and consequently saferfor use in therapy. Since the E1 gene products are required for viral growth, they are provided in trans in specific cell lines to allow production and amplification of the vectors. Vectors in which only the E3 region is deleted are replication competent.
  • the invention provides an adenoviral vector comprising a sequence selected from SEQ ID NOs:1 -3, 5-8, 10-12, 14-15, 17-25 and 27-32, or a sequence at least 50% identical thereto, that lacks the E1 region.
  • the sequence is at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to a sequence selected from SEQ ID NOs:1 -3, 5-8, 10-12, 14-15, 17-25 and 27-32.
  • the invention provides an adenoviral vector comprising a sequence selected from SEQ ID NOs:1 -8, 10-12, 14-15 and 17-32, or a sequence at least 50% identical thereto, that lacks the E1 region and the E3 region.
  • the sequence is at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to a sequence selected from SEQ ID NOs:1 -8, 10-12, 14-15 and 17-32.
  • the invention provides an adenoviral vector comprising a sequence selected from SEQ ID NOs:1 -3, 5-12, 14-15 and 17-32, or a sequence at least 50% identical thereto, that lacks the E3 region.
  • the sequence is at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to a sequence selected from SEQ ID NOs:1 -3, 5-12, 14-15 and 17-32.
  • Hybrid vectors with a fiber protein from a different serotype can be constructed, as described above. Accordingly, the first-generation vectors may have the fiber gene replaced with a fiber gene from a different adenoviral serotype, selected from SEQ ID NOs:129-143 and 145-160, or a sequence at least 70% identical thereto (preferably at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical).
  • E1 -deleted vectors can accept DNA insertions of up to around 5.1 kb.
  • Vectors lacking both the E1 and the E3 regions can accommodate up to around 8.2 kb of foreign DNA 19 .
  • a transgene (or one or more transgenes) inserted into the first generation adenoviral vectors of the invention may be up to around 5.1 kb in size in total if E1 is deleted, or up to around 8.2 kb in size in total if E1 and E3 are deleted. It may be beneficial to retain the E3 region in some cases, as the E3 gene products include proteins which facilitate release of virus particles from cells and reduce cytotoxic T cell responses against cells transduced with the vector.
  • helper vectors can be used, for example, as helper vectors, oncolytic vectors, or vaccine vectors.
  • Helper vectors should be replication deficient.
  • Oncolytic vectors are replication competent.
  • Vaccine vectors may be replication deficient, but are preferably replication competent as this may lead to the induction of better immune responses.
  • High-capacity adenoviral vectors lack all viral coding sequences. The benefit of such vectors is that they can accommodate much larger transgenes, or multiple transgenes, than the first generation vectors in which only some coding sequences are deleted.
  • the only required sequences from the viral genome are cis-acting elements located at both ends of the adenoviral DNA molecule, which should include the packaging signal ( ⁇ ) located at the 5' end of the genome, and the inverted terminal repeats (ITRs) at both ends of the adenoviral genome.
  • the ITR is 103 bp in length and the packaging/enhancer sequences span nucleotides 194-458 bp located at the left arm of the adenoviral genome.
  • 500bp at the 5' end of the genome will comprise the 5' ITR and the packaging signal
  • 150bp at the 3' end of the genome will comprise the 3' ITR.
  • high-capacity adenoviral vectors lack all viral coding regions, they are constructed and propagated in conjunction with an adenoviral helper vector, which provides the necessary viral functions (early and late proteins necessary for replication) in trans (see below).
  • the high-capacity vectors can be separated from the helper vectors, for example by ultracentrifugation on cesium chloride density gradients and/or anion exchange and size exclusion chromatography.
  • High-capacity adenoviral vectors can accommodate up to around 37 kb of foreign genetic material (e.g. one large transgene, or more than one transgene), and they are therefore useful for carrying large transgenes or multiple transgenes (e.g. 2, 3, 4, 5 or more transgenes) and/or other heterologous DNA sequences.
  • foreign genetic material e.g. one large transgene, or more than one transgene
  • transgenes e.g. 2, 3, 4, 5 or more transgenes
  • the invention provides an adenoviral vector comprising a sequence selected from the sequences contained within SEQ ID NO: 1 -13 and 18-32 at the positions defined in Table 1 , column 4 or a sequence at least 80% identical thereto, at the 5' end, and the positions defined in Table 1 , column 5, or a sequence at least 80% identical thereto, at the 3' end.
  • the sequences are at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to the sequences contained within SEQ ID NO: 1 -13 and 18-32 at the positions defined in Table 1 , column 4, and the positions defined in Table 1 , column 5.
  • the invention provides an adenoviral vector comprising a sequence selected from SEQ ID NOs:33-45 and 50-64, or a sequence at least 80% identical thereto, at the 5' end, and a sequence selected from SEQ ID NOs:97-109 and 1 14-128, or a sequence at least 80% identical thereto, at the 3' end.
  • sequences are at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NOs:33-45, 50-64, 97-109 and 1 14-128.
  • gene deleted high-capacity adenoviral vectors (HCAdVs) of the invention may offer the ability to delivery one or more large genes to a cell of interest.
  • a gene-deleted high-capacity adenoviral vector has a packing capacity of at least 15kb, e.g. at least 20, 25, 30, 35, 40 or 45kb.
  • the gene-deleted high-capacity adenoviral vector comprises at least 15kb, e.g. at least 20, 25, 30, 35, 40 or 45kb, of DNA which is non-adenoviral genome sequence .
  • the high-capacity adenoviral vectors of the invention may be used to deliver the components of the CRISPR/Cas9 system.
  • the advantage of using the high-capacity adenovirus vectors for this purpose is that a single viral vector can be used, optionally with multiple guide RNAs. They may also be used to deliver transcription activator-like effector nucleases (TALENs) or zinc-finger nucleases (ZFNs).
  • TALENs transcription activator-like effector nucleases
  • ZFNs zinc-finger nucleases
  • a respective donor DNA which can be delivered by an adenoviral vector or an adeno-associated viral (AAV) vector
  • the mutated gene can be repaired by homology-directed DNA repair.
  • vectors can be used to treat infectious disease, for example as an antiviral approach to cut and destroy viral genomes.
  • the invention provides these uses accordingly.
  • the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system allows for straightforward in vivo genome editing. Nevertheless, viral delivery of all required components including Cas9 and one or more guide RNA (gRNA) expression units using one single viral vector has not been fully exploited.
  • HCAdVs Gene deleted high-capacity adenoviral vectors
  • CRISPR/Cas9 machinery including multiple gRNAs
  • the present inventors have provided a toolbox for HCAdV genome manipulation for the fast and simple introduction of the customized CRISPR/Cas9 machinery to provide new instruments to improve somatic genome editing approaches in mammalian cells.
  • the inventors generated a new CRISPR/Cas9 shuttle plasmid toolbox containing the Cas9 nuclease gene, either utilising a constitutive or an inducible promoter, and a gRNA expression unit enabling customisation of the CRISPR/Cas9 for a desired target sequence.
  • This allows cloning or recombining of all CRISPR/Cas9 components into the HCAdV genome in one step.
  • further gRNA expression units can be easily included. Insertion of the CRISPR/Cas9 machinery can be either performed by recombineering 20 or conventional cloning.
  • the invention provides a plasmid which shares at least two regions of sequence homology with an adenoviral sequence of interest and which comprises the Cas9 gene and a guide RNA expression unit.
  • the Cas9 gene is under control of a constitutive promoter.
  • the Cas9 gene is under control of an inducible promoter. The regions of sequence homology may be designed to allow the Cas9 gene to be inserted into a chosen location in the adenoviral sequence.
  • the at least two regions of sequence homology are designed so that the Cas9 gene and the gRNA expression unit are inserted into the E3 region of the adenoviral sequence.
  • the plasmid is the pAdV-FTC plasmid. Such a plasmid may be used in the methods of inserting one or more transgenes described herein as the second nucleic acid molecule.
  • the invention provides an adenoviral vector comprising a sequence selected from the sequences contained within SEQ ID NO: 1 -13 and 18-32 at the positions defined in Table 1 , column 4 or a sequence at least 80% identical thereto, at the 5' end, and the positions defined in Table 1 , column 5, or a sequence at least 80% identical thereto, at the 3' end, and further comprising a Cas9 gene and at least one guide RNA.
  • the degree of sequence identity is at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9%.
  • the invention provides an adenoviral vector comprising a sequence selected from SEQ ID NOs:33-45 and 50-64, or a sequence at least 80% identical thereto, at the 5' end, and a sequence selected from SEQ ID NOs:97-109 and 1 14-128, or a sequence at least 80% identical thereto, at the 3' end, and further comprising a Cas9 gene and at least one guide RNA.
  • the degree of sequence identity is at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9%.
  • the vector may comprise more than one guide RNA, for example two, three, four, five, eight, 10, 15, 20, 25, 30, 40, 50 or more guide RNAs.
  • the Cas9 gene may be expressed under the control of a constitutive or an inducible promoter.
  • the invention provides an adenoviral vector as described herein, further comprising a gene encoding a transcription activator-like effector nuclease (TALEN) or a zinc-finger nuclease.
  • the adenoviral vectors disclosed herein comprise at least 1 kb of non- adenoviral sequence, e.g. at least 2, 5, 10, 15, 20, 25, 30, 35 or 40 kb non-adenoviral sequence.
  • the non-adenoviral sequence encodes one or more transgenes of interest.
  • the non-adenoviral sequence is not plasmid sequence.
  • the high-capacity adenoviral vectors of the invention may be utilised in conjunction with the Sleeping Beauty transposon system, or other transposon systems such as PiggyBAC 22 , to facilitate stable modification of transduced target cells.
  • Any cell type, including stem cells, can be modified by the adenovirus-Sleeping Beauty hybrid vector system 23 .
  • the invention provides an adenoviral vector comprising a sequence selected from the sequences contained within SEQ ID NO: 1 -13 and 18-32 at the positions defined in Table 1 , column 4 or a sequence at least 80% identical thereto, at the 5' end, and the positions defined in Table 1 , column 5, or a sequence at least 80% identical thereto, at the 3' end, and further comprising a Sleeping Beauty transposase gene (SEQ ID NO:223) and a transgene flanked by the inverted repeats of the Sleeping Beauty transposon (SEQ ID NOs:224 and 225), or comprising a PIGGYBac transposase gene (SEQ ID NO:226) and a transgene flanked by the inverted repeats of the PIGGYBac transposon.
  • the sequences are at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to the sequences contained within SEQ ID NO: 1 -13 and 18-32 at the positions defined in Table 1 , column 4, and the positions defined in Table 1 , column 5.
  • the invention provides an adenoviral vector comprising a sequence selected from SEQ ID NOs:33-45 and 50-64, or a sequence at least 80% identical thereto, at the 5' end, and a sequence selected from SEQ ID NOs:97-109 and 1 14-128, or a sequence at least 80% identical thereto, at the 3' end, and further comprising a Sleeping Beauty transposase gene (SEQ ID NO:223) and a transgene flanked by the inverted repeats of the Sleeping Beauty transposon (SEQ ID NOs:224 and 225), or comprising a PIGGYBac transposase gene (SEQ ID NO:226) and a transgene flanked by the inverted repeats of the PIGGYBac transposon.
  • SEQ ID NO:223 a sequence selected from SEQ ID NOs:33-45 and 50-64, or a sequence at least 80% identical thereto, at the 5' end, and a sequence selected from SEQ ID
  • the sequences are at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NOs:33-45, 50-64, 97-109 and 1 14-128.
  • the transposase is expressed under the control of an inducible promoter. It is particularly preferred that this should be a cell-specific promoter, permitting expression of the transgene only in target cells of interest.
  • the adenovirus-Sleeping Beauty or adenovirus-PiggyBac hybrid vectors of the invention can be used to stably integrate transgenes into stem cells, e.g. hematopoietic stem cells.
  • the main advantage of this strategy is that it avoids the sophisticated ex vivo transduction procedure usually required to transform hematopoietic stem cells. Instead, these stem cells can be directly transduced in vivo after mobilisation form the bone marrow and subsequent systemic administration of the hybrid vectors.
  • Transgenes that can be stably integrated into these stem cells include those encoding coagulation factor VIII, coagulation factor IX, von Willebrand factor, haemoglobin, and other genes involved in genetic disorders derived from HSCs.
  • the adenoviral vectors of the invention may include any transgene (or more than one transgene). Transgenes with therapeutic utility are preferred.
  • Transgenes of particular interest in human gene therapy are listed below by way of example, but other transgenes may also be included in the adenoviral vectors of the invention.
  • Von Willebrand disease VWD
  • vWF the large transgene encoding von Willebrand factor
  • the adenovirus vectors of the present invention can be used to achieve endothelial cell-specific vWF expression (endothelial cells are the natural producer cell type of vWF).
  • endothelial cells are the natural producer cell type of vWF.
  • vectors based on HAdV D17 which have an endothelial cell tropism, can be used for endothelial cell-specific vWF expression.
  • Coagulation factor VIII (FVIII) deficiency / haemophilia A - the large transgene encoding FVIII (Accession No. NM_000132) can be delivered using the high-capacity adenoviral vectors of the invention. The transgene can be subsequently mobilised for somatic integration into the host genome using the high-capacity adenovirus/ Sleeping Beauty hybrid vectors.
  • Beta-thalassemia - the haemoglobin gene can be included in the adenovirus vectors of the invention to treat the haemoglobin deficiency that causes beta- thalassemia.
  • Muscular dystrophy - Dystrophin gene DMD
  • Cystic fibrosis - cystic fibrosis (CF) gene accesion No. NM_000492).
  • Adenoviral helper vectors can be included in the adenovirus vectors of the invention to treat the haemoglobin deficiency that causes beta- thalassemia.
  • Muscular dystrophy - Dystrophin gene DMD
  • Cystic fibrosis - cystic fibrosis (CF) gene accesion No. NM_000492.
  • Adenoviral helper vectors are used in conjunction with the high-capacity adenoviral vectors of the invention to facilitate their construction and propagation.
  • the helper adenovirus provides all or most of the required early and late proteins necessary for replication.
  • the helper vector has loxP sites or FRT sites flanking the packaging signal such that packaging of the helper vector is avoided, resulting in preferential packaging of the high-capacity adenoviral genome.
  • the invention provides an adenoviral helper vector comprising a sequence selected from SEQ ID NOs:1 -13 and 18-32, or a sequence at least 50% identical thereto, that lacks the E1 region and comprises loxP sites (SEQ ID NO:221 ) or FRT sites (SEQ ID NO:222), wherein the loxP or FRT sites are positioned such that the first is downstream of the part of the sequence corresponding the positions defined in Table 1 , column 3 , respectively, and the second is upstream of the position of the deleted E1 region and downstream of the part of the sequence corresponding to the positions defined in Table 1 , column 4 , respectively.
  • the invention provides an adenoviral helper vector comprising a sequence selected from SEQ ID NOs:1 -13 and 18-32, or a sequence at least 50% identical thereto, that lacks the E1 region and comprises loxP sites (SEQ ID NO:221 ) or FRT sites (SEQ ID NO:222), wherein the loxP or FRT sites are positioned such that the first is downstream of the part of the sequence corresponding to SEQ ID NOs:65-77 and 82-96, respectively, and the second is upstream of the position of the deleted E1 region and downstream of the part of the sequence corresponding to SEQ ID NOs:33-45 and 50-64, respectively.
  • the sequence is at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to a sequence selected from SEQ ID NOs:1 -13 and 18-32.
  • Hybrid helper vectors may be constructed as described above for the first-generation vectors of the invention.
  • Adenoviral vaccine vectors may be constructed as described above for the first-generation vectors of the invention.
  • Adenoviral vectors can also be used as vaccine vectors to deliver and express transgenes from a pathogen to raise an immune response.
  • Adenoviral vectors tend to induce strong humoral and especially strong T cell responses to the expressed antigen 25 .
  • Adenoviral vaccine vectors can be replication-competent or replication-deficient.
  • the immune response varies depending on the adenovirus serotype, and consequently the protection efficiency against the vaccine antigen may be improved using adenoviral vectors based on adenoviruses from the different serotypes forming part of the library disclosed herein 24 .
  • Replication-competent adenovirus vectors have the E3 gene deleted and replaced by heterologous DNA.
  • the antigen may be expressed as part of an antigen expression cassette (e.g. under the control of a constitutive or inducible promoter), or via a bicistronic IRES sequence or a P2A peptide in the context of an early or late adenovirus transcription unit.
  • an antigen expression cassette is inserted into the E3 region. This may be done, for example, using the strategy described in Example 1 for the GFP/luciferase tagged adenoviruses. Further information regarding adenovirus vectors for use in vaccination may be found in reference 25, which is incorporated herein by reference.
  • the invention provides an adenoviral vaccine vector comprising a gene encoding and capable of expressing an antigen.
  • the vaccine vector may be a first generation adenoviral vector as described above, or a high-capacity adenoviral vector as described above.
  • the antigen may be from any pathogen, but is preferably from human immunodeficiency virus (HIV), Ebolavirus, Zika virus, hepatitis B virus, hepatitis C virus, influenza virus, Mycobacterium tuberculosis, or Plasmodium falciparum.
  • HAV human immunodeficiency virus
  • Ebolavirus Ebolavirus
  • Zika virus hepatitis B virus
  • hepatitis C virus influenza virus
  • Mycobacterium tuberculosis hepatitis C virus
  • Plasmodium falciparum Plasmodium falciparum
  • Suitable HIV antigens include (but are not limited to) Gag, Pol and Nef 26 .
  • Suitable Ebolavirus antigens include the EBOV glycoprotein 27 .
  • Suitable Zika virus antigens include Zika virus glycoproteins.
  • Suitable hepatitis B antigens include the surface antigen (HBsAg).
  • Suitable hepatitis C antigens include NS3-5B 28 .
  • Suitable influenza virus antigens include neuraminidase (NA), hemagglutinin (HA), nucleoprotein (NP) and matrix protein (MP). Producer cell lines
  • the adenovirus vectors and helper vectors of the invention may lack the E1 region. However, this region contains genes necessary for viral replication, and so E1 -expressing cell lines are required in order to generate adenoviral particles for delivery of the vectors to cells.
  • the invention provides a cell encoding, and capable of expressing, an adenoviral E1 region derived from SEQ ID NO:1 -3, 5-8, 10-12, 14-15, 17-25 or 27-32, or a sequence at least 70% identical to said E1 region.
  • Such cells are used for producing adenovirus vectors according to the invention.
  • the sequence is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to the adenoviral E1 region derived from SEQ ID NO:1 -3, 5-8, 10-12, 14-15, 17-25 or 27-32.
  • the invention provides a eukaryotic cell that has been transfected with an adenovirus vector as described herein that has been released from the adenovirus plasmid by restriction enzyme digestion.
  • the cell may further be capable of expressing Cre recombinase (Accession No. P06956) or Flp recombinase (Accession No. P03870). This is useful when using a helper vector in which the packaging signal is flanked by loxP or FRT sites, respectively, to allow preferential packaging of the helper-dependent vector over the helper vector, as discussed above.
  • Preferred cell lines include HEK293, HeLa and A549, but other cells can also be used.
  • Oncolytic adenoviral vectors include HEK293, HeLa and A549, but other cells can also be used.
  • Oncolytic adenoviruses can be used in cancer therapy. Selective replication of these viruses in cancer cells can lead to killing of infected cells by virus-mediated cytolysis, and spreading to neighbouring tumour cells to continue the oncolytic process.
  • Oncolytic adenoviral vectors should be replication competent. That is, the oncolytic adenovirus should still be able to assemble and release new virus particles to infect neighbouring cells. Therefore it should contain at least all essential genes (transcription units E1 , E2, E4 and L1 -L5). E1 and E2, which are mainly responsible for virus replication, can be mutated or partially deleted to enhance replication efficiencies or to render the recombinant virus tumour-specific.
  • the invention provides an oncolytic adenoviral vector comprising an E1 region derived from SEQ ID NOs:1 -8, 10-12, 14-15, 18-25 or 27-32, or a sequence at least 70% identical to said E1 region.
  • the sequence is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to said E1 region.
  • the oncolytic vector further comprises:
  • E2 region derived from SEQ ID NOs:1 -8, 10-12, 14-15, 18-25 or 27-32, or a sequence at least 70% identical to said E2 region;
  • E4 region derived from SEQ ID NOs:1 -8, 10-12, 14-15, 18-25 or 27-32, or a sequence at least 70% identical to said E4 region;
  • L1 region derived from SEQ ID NOs:1 -8, 10-12, 14-15, 18-25 or 27-32, or a sequence at least 70% identical to said L1 region;
  • L3 region derived from SEQ ID NOs:1 -8, 10-12, 14-15, 18-25 or 27-32, or a sequence at least 70% identical to said L3 region;
  • L4 region derived from SEQ ID NOs:1 -8, 10-12, 14-15, 18-25 or 27-32, or a sequence at least 70% identical to said L4 region;
  • the degree of sequence identity is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9%, for each of the regions.
  • the E1 and/or E2 region of the oncolytic vector may be mutated or partially deleted to enhance replication efficiency and/or tumour specificity (e.g. specificity of replication in tumour cells).
  • tumour specificity e.g. specificity of replication in tumour cells.
  • a deletion may be made in the early gene E1 B that inactivates p53. Suitable deletions have been made in HAd5-based vectors (ONYX-015 and H101 ); however, any deletion in E1 B that has the effect of inactivating p53 may be used. Such viruses are useful in p53-functional cells.
  • oncolytic adenoviruses may contain a 24 bp deletion in the CR2 region of the E1A region (as in AdA24). This mutation helps to restrict replication to cancer cells with mutated pRb (retinoblastoma protein). Further details of these and other mutations to enhance replication specificity can be found in reference 29 and the references cited therein (which are incorporated herein by reference). Part or all or the E3 region may also be mutated or deleted to enhance antitumour effects, example, deletion of the E3B gene enhances antitumour effects in immunocompetent mice 30 .
  • the serotype from which viral sequences are derived may also be chosen to maximise replication.
  • vectors based on the hAd6 sequences disclosed herein appear to have enhanced oncolytic activity relative to human adenovirus 5 (see Example 6). Without being bound by any particular theory, it is thought that this enhanced oncolytic activity may be the result of enhanced replication. Vectors with enhanced replication or enhanced oncolytic activity relative to human adenovirus 5 are particularly preferred. The use of vectors comprising the Ad6 sequence in embodiments which comprise oncolysis is therefore encompassed by the present invention.
  • the virus can be armed using genes which enhance tumour cell killing or replication. Enhancing replication and production of new progeny is highly desirable, as in many cases virus-induced cell killing is not efficient enough.
  • the oncolytic vectors of the invention may further comprise:
  • tumour- or tissue-selective promoter e) a tumour- or tissue-selective promoter
  • Immunostimulatory genes can recruit immune cells to tumours and activate them. Recruitment of the immune system helps to destroy the primary tumour as well as having the potential to act on and clear metastatic cells.
  • Genes encoding cytokines such as monocyte chemotactic protein 3 (MCP3) or granulocyte-macrophage colony-stimulating factor (GM-CSF) can be included in the oncolytic vectors. Other cytokines also result in enhanced immune responses and antitumour toxicity, for example tumour necrosis factor alpha (TNFa) and interferon gamma (IFNv). Various interleukins and heat shock proteins can also be used 33 .
  • TNFa tumour necrosis factor alpha
  • IFNv interferon gamma
  • Various interleukins and heat shock proteins can also be used 33 .
  • Suicide genes and interfering nucleic acids that enhance cell killing
  • suicide genes that encode prodrug-converting enzymes that convert non-toxic prodrugs to toxic products, are particularly effective as the toxic products can lead to killing of neighbouring, non-infected cells.
  • the herpes simplex virus thymidine kinase gene HSV-TK
  • ganciclovir ganciclovir
  • CD cytosine deaminase
  • tumour suppressor genes such as p53, or viral genes which stimulate cell senescence such as the Ad death protein (E3-1 1.6K) may be incorporated into vectors of the invention.
  • the Ad death protein also enhances viral spread.
  • cytokine signalling 3 suppressor of cytokine signalling 3 (socs3), second mitochondria-derived activator of caspases (Smac), X-linked inhibitor of apoptosis protein (XIAP)-associated factor 1 (XAF1 ), antioxidant enzyme manganese superoxide dismutase (MnSOD), and TNF-related apoptosis- incuding ligand (TRAIL).
  • sercs3 suppressor of cytokine signalling 3
  • Smac second mitochondria-derived activator of caspases
  • XIAP X-linked inhibitor of apoptosis protein
  • XAF1 antioxidant enzyme manganese superoxide dismutase
  • TRAIL TNF-related apoptosis- incuding ligand
  • Interfering nucleic acids against antiapoptotic proteins can also be used.
  • antisense RNAs against cellular checkpoint proteins e.g.
  • polo-like kinase 1 plkl
  • checkpoint kinase 1 chkl
  • checkpoint kinase 2 chk2
  • small interfering RNAs siRNAs
  • Some of these genes and interfering nucleic acids result in induced synergistic oncolytic effects when combined with chemotherapeutic agents such as 5-fluorouracil and cisplatin 33 .
  • chemotherapeutic agents such as 5-fluorouracil and cisplatin 33 .
  • Tumour or tissue-selective promoters allow further specificity of replication in tumour cells.
  • CN706 has a prostate-specific antigen promoter-driven E1 cassette, which allows selective, androgen-dependent replication in prostate cells 32 .
  • the oncolytic vectors may carry transgenes that act on extracellular matrix components, such as tissue inhibitor of metalloproteinase 3 (TIMP3), or transgenes that inhibit angiogenesis, such as endostatin, Flt-1 (a VEGF inhibitor), or interfering RNAs targeted against angiogenesis-promoting factors such as VEGF.
  • TIMP3 tissue inhibitor of metalloproteinase 3
  • transgenes that inhibit angiogenesis such as endostatin, Flt-1 (a VEGF inhibitor)
  • interfering RNAs targeted against angiogenesis-promoting factors such as VEGF.
  • the above transgenes may be placed under the control of endogenous viral gene control elements, or may be under the control of exogenous promoters. Exogenous promoters may be constitutive or inducible. Further details of suitable transgenes and promoters as discussed above can be found in references 29 and 33 and the references cited therein (which are incorporated by reference herein).
  • the fiber gene region is primarily responsible for cell tropism. If the target tumour cells express a receptor to which a fiber protein from the adenoviral library binds, an oncolytic vector can be based on this adenoviral serotype, or a hybrid oncolytic vector may be constructed comprising only the fiber gene (or the shaft and knob regions thereof) from said adenoviral serotype, as described above for the first-generation vectors of the invention.
  • the invention also provides pharmaceutical compositions comprising the adenoviral vectors of the invention, including vectors for use in gene therapy, vaccine vectors and oncolytic vectors.
  • the pharmaceutical compositions comprise the vector of the invention and a pharmaceutically- acceptable carrier.
  • compositions of the invention may comprise further excipients.
  • a pharmaceutical composition comprising an oncolytic adenoviral vector of the invention may comprise a polymer or polyethylene glycol coating for the oncolytic vector. This may aid immune evasion and increase delivery to the tumour 34,35 .
  • compositions of the invention may comprise further therapeutic agents in addition to the adenoviral vector.
  • compositions comprising an oncolytic vector may comprise one or more further chemotherapeutic agents (e.g. 5-fluorouracil and cisplatin), particularly if the oncolytic vector increases susceptibility to therapy with other drugs.
  • the adenoviral vectors or the oncolytic adenoviruses of the invention may be used in therapy.
  • the invention also provides a method of treatment comprising administering an adenoviral vector of the invention to a patient.
  • adenoviral vectors of the invention may be used in gene therapy.
  • Such vectors include a transgene, for example the transgenes discussed above for the treatment of von Willebrand disease, haemophilia A, beta thalassemia, muscular dystrophy and cystic fibrosis.
  • the invention is not limited to treatment of these disorders, and in principle, the vectors of the invention can be used to treat any genetic disorder in which replacement of a mutant allele with a non-mutant copy could restore physiological function.
  • Vectors for use in gene therapy include the first generation adenoviral vectors and the high-capacity adenoviral vectors described above.
  • the adenovirus-Sleeping Beauty hybrid vectors of the invention can be used.
  • the CRISPR/Cas9 high-capacity vectors can be used to facilitate in vivo gene correction to treat genetic diseases, as discussed above.
  • CRISPR/Cas9 vectors of the invention can be used to treat infectious diseases, for example as an antiviral approach to cut and destroy viral genomes.
  • Adenoviral vaccine vectors of the invention can be used as prophylactic and/or therapeutic vaccines.
  • Vaccine vectors can be used to protect against various diseases, for example including HIV, Ebola, Zika virus disease, hepatitis B, hepatitis C, influenza, tuberculosis or malaria.
  • Oncolytic vectors of the invention can be used to treat conditions involving the formation of benign and/or malignant tumours, including cancer.
  • the oncolytic vectors can be used to treat carcinoma (e.g. squamous cell or nasopharyngeal), colorectal cancer, hepatocellular carcinoma, lung cancer, mesothelioma, prostate cancer, breast cancer, ovarian cancer, bladder cancer, glioma etc.
  • the vectors of the invention may be administered locally or systemically.
  • Systemic administration may include intravenous, intraarterial, intraperitoneal, intramuscular, intramuscular or subcutaneous administration.
  • the vectors may be administered mucosally (e.g. orally or nasally).
  • Local administration can include e.g. local delivery to target tissues for gene therapy (e.g. intrapleurally), or intratumoral or intracavitary delivery for oncolytic adenoviruses.
  • Vectors for use in therapy may be administered in conjunction with other therapeutic agents, either as part of the same composition, or as separate compositions administered together or sequentially.
  • treatment with an oncolytic vector may be administered in conjunction with other chemotherapeutic agents (e.g. 5-fluorouracil and cisplatin), or may be used in conjunction with e.g. radiotherapy.
  • chemotherapeutic agents e.g. 5-fluorouracil and cisplatin
  • a method for determining whether an adenovirus is present in a sample may be used for determining whether a disease is being caused by an adenoviral infection.
  • the invention further provides a method for diagnosing a disease, e.g. an infection, as being caused by an adenovirus, comprising carrying out a method as described above, wherein the sample is a clinical sample from the patient (e.g. blood, saliva, urine or serum) or genomic DNA derived from the sample.
  • the patient is selected from a human or non-human mammal, for example, horse, dog, cat, cow, goat, sheep, rabbit, mouse, rat or guinea pig.
  • the patient is a human.
  • the invention further provides a method for determining the identity of an adenovirus in a patient sample by carrying out a method as described above.
  • the disease is selected from a disease of the respiratory tract, eye, intestine, urinary tract and nervous system.
  • the disease of the respiratory tract is a respiratory infection, for example, bronchiolitis, croup, or viral pneumonia.
  • the disease of the intestine is gastroenteritis or diarrhea.
  • the disease of the eye is conjunctivitis, pharyngoconjunctival fever, or keratoconjunctivitis.
  • the disease of the urinary tract is a urinary tract infection or hemorrhagic cystitis.
  • the disease is meningitis or encephalitis.
  • the disease is febrile respiratory disease.
  • the invention provides a method of generating an adenoviral vector or helper vector as defined above. This includes methods of producing the vaccine vectors or oncolytic vectors as defined above.
  • a method of generating an adenoviral vector comprises cloning an adenoviral sequence using linear to linear homologous recombination (LLHR).
  • LLHR linear to linear homologous recombination
  • the invention provides a method for cloning an adenoviral sequence, comprising:
  • the adenoviral sequence is an adenoviral sequence as disclosed herein.
  • the first linear nucleic acid molecule comprising an adenoviral sequence is present in a biological fluid obtained from a human or other non-human mammal.
  • the sample is blood, serum, spinal fluid, saliva and/or urine.
  • the sample is a mixture.
  • the sample is a clinical sample. This mixture may, in some embodiments, comprise adenoviral genomic DNA and eukaryotic genomic DNA, for example human genomic DNA.
  • the method of the present invention allows adenoviruses to be cloned directly from a biological sample without requiring a step of purifying the DNA before carrying out the cloning step.
  • a DNA mixture isolated from cell/virus lysate can be used instead of using a purified adenovirus genome.
  • the method further comprises a step of amplifying the adenovirus in a cell line before lysing the cells.
  • the first linear nucleic acid molecule is present in a cell/virus lysate or is present in a DNA mixture isolated from cell/virus lysate.
  • the method involves co-electroporating the first linear nuclear molecule present in a mixture isolated from cell/virus lysate into a host cell together with the plasmid of step b) such that homologous recombination can occur.
  • the method comprises a step of phenol-chloroform extraction to isolate the adenoviral DNA from the sample.
  • the phenol- chloroform extraction involves taking the interphase protein-DNA complexes.
  • the mixture comprising adenoviral DNA is treated with proteinase K.
  • viral genomic DNA is extracted, e.g. from purified particles, by the addition of proteinase K, subsequent phenol-chloroform extraction, and ethanol precipitation.
  • less than 2 ug e.g. less than 1 .75ug, less than 1 .5 ug, less than 1 .25 ug
  • more than 200 ng e.g. more than 300ng, 500ng, 700ng, 800ng, 900ng
  • the amount of plasmid vector used in the cloning method is about the same as the amount of viral genomic DNA.
  • about 1 ug viral genomic DNA is used in the cloning method together with about 1 ug plasmid vector. As shown in Figure 2, very good efficiencies of homologous recombination are obtained using these amounts.
  • the method may comprise amplifying the adenovirus in a cell line, lysing the cells and purifying the virus from the crude cell lysate, e.g. by CsCI gradient, followed by viral genome isolation and sequence verification. Once the sequence of the ITR regions has been obtained, the method of cloning described herein can be used to clone the full length adenovirus.
  • a plasmid that has been designed to have sequence homology to the ITRs of one adenovirus to clone a different adenovirus
  • the present invention also encompasses such embodiments.
  • the direct cloning method described herein advantageously provides a more efficient and quicker method for cloning full length adenoviral genomes than was previously available.
  • most adenoviral cloning techniques involved modularly cloning regions of adenoviral genes and stitching them together in a BAC vector.
  • the linearized plasmid is designed so that it comprises a region of sequence homology with the 5' ITR of the adenoviral sequence in the first linear nucleic acid molecule and a region of sequence homology with the 3' ITR of the adenoviral sequence in the first linear nucleic acid molecule.
  • the region of homology is about 50nt in length, for example, 50nt, 50-55nt, 50-60nt, 50-70nt, 45-50nt, 40-50nt, 30-50nt, 45-55nt, 40-60nt, 30-70nt or 40-80nt in length.
  • the region of sequence homology is 100% identical with the respective region of the adenoviral sequence. In some embodiments, there is a lesser degree of sequence identity (e.g. more than 90%, more than 95%, more than 98%), but there is sufficient sequence homology for homologous recombination to occur. This enables a plasmid vector designed to clone a first adenovirus to be used to clone a second adenovirus whose ITR regions share sufficient sequence homology with the first adenovirus.
  • the region of homology is only to a part of the ITR sequence rather than to the full length ITR sequence. In some embodiments, the region of homology is to the whole length of the ITR sequence.
  • the 5' ITR and 3' ITR sequences are at the 5' and 3' ITR of the adenoviral genome and so designing the linearized plasmid so that these are the regions to be recombined ensures that the full length genome is cloned into the plasmid backbone. It would be straightforward for the skilled person to obtain the 5' and 3' ITR sequences from an adenoviral genome sequence, for example, from an adenoviral genome sequence as disclosed herein. In some embodiments, the 5' and 3' ITR sequences are from an adenoviral genome sequence as presented in Table 1 , columns 3 and 5 respectively.
  • the first linear nucleic acid molecule comprises a full length adenoviral genome sequence.
  • such a sequence will be present in the sample because of the presence of adenovirus in the sample.
  • the adenoviral sequence is the full length adenoviral genome sequence contained within any one of SEQ ID Nos 1 -32 and/or 141 1 , for example, contained within any one of SEQ ID Nos 1 -15, 17-32 and/or 141 1 or contained within any one of SEQ ID NOs: 1 -3, 5-8, 10-12, 14-15, 17-25 and 27-32 and/or 141 1 , or contained within any one of SEQ ID NOs: 1 -3, 5-8, 10-12, 14-15, 17-25 and 27-32, or a sequence at least 50% identical thereto.
  • the circular plasmid formed in step c) comprises a full length adenoviral genome sequence.
  • the adenoviral genome sequence cloned into the circular plasmid in step c) is missing one or more nucleotides at its 5' and/or 3' ends because one or both regions of sequence homology did not extend all the way to the 5' and/or 3' terminus, respectively, of the ITR sequence.
  • the adenoviral genome sequence is missing less than 3, 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 125 or 135 nucleotides from its 5' and/or 3' ends.
  • a method for cloning an adenoviral genome sequence comprising:
  • the linearized plasmid comprises homology arms (HA) for directed cloning containing the 5' and 3' ITR sequences, one or more selection markers and an origin of replication.
  • the linearized plasmid comprises homology arms (HA) for directed cloning containing the 5' and 3' ITR sequences, one or more selection markers (e.g. the chloramphenicol resistance gene) and an origin of replication (e.g. the p15a origin).
  • the linearized plasmid comprises homology arms (HA) for directed cloning containing the 5' and 3' ITR sequences, one or more selection markers (for example, ccdB10 and ampicillin for advanced positive and counter selection), an origin of replication (e.g. p15A) and an antibiotic resistance gene (e.g. the chloramphenicol resistance gene).
  • HA homology arms
  • selection markers for example, ccdB10 and ampicillin for advanced positive and counter selection
  • an origin of replication e.g. p15A
  • an antibiotic resistance gene e.g. the chloramphenicol resistance gene.
  • the linearized plasmid is selected from a p15A origin-based vector, a pBR322 origin- based vector, a fosmid, a pUC origin-based vector or a ColE1 origin-based vector.
  • Medium copy plasmids are preferred, for example, p15A, pBR322, pR6K, pRK2, pBBR1 and Inc-based plasmids, in particular p15A origin-based vectors.
  • the medium copy plasmid is p15A-cm-adHA, as described herein.
  • the plasmid is present in about 10 copies in each cell, for example 10 copies, 9-1 1 , 8-12, 8-1 1 or 6-12 copies.
  • the plasmid used for cloning the adenovirus genome sequence is not a BAC.
  • the plasmid is a shuttle vector.
  • the plasmid is less than 4kb in length, for example, less than 3.5kb, 3kb, 2.5kb, 2kb, 1.5kb or 1 kb in length.
  • Cloning the adenoviral genome into a medium copy plasmid provides a number of advantages compared to prior art methods which involved cloning adenoviral sequences into low copy BACs.
  • the present adenoviral plasmids allow a higher concentration of adenoviral vector to be obtained and increase the efficiency of transfection of the released adenovirus vectors into cells.
  • the plasmid backbones described herein are more stable than the prior art backbones and make it possible to clone complete adenovirus genomes in a high-throughput manner without introducing recombinations or mutations into the cloned viral genome.
  • the increased efficiency of the present method means the number of clones that need to be screened to find a correct recombinant is greatly reduced compared to the prior art methods which often required screening of around 400 clones.
  • the cloning methods described herein make it possible to create a library of adenoviral genome sequences and adenoviral vectors, which was simply not feasible using the previous techniques.
  • medium copy plasmids such as a p15A origin plasmid
  • a medium copy plasmid has a number of advantages compared to BACs.
  • medium copy plasmids such as p15A can be more stable than BACs.
  • the medium copy plasmid makes the first cloning step easier become the homology arms can be ordered as oligonucleotides and attached to the plasmid by PCR in one or two steps, whereas each homology arm must be cloned into the BAC individually to generate a dedicated plasmid that then must be linearized,.
  • medium copy plasmids such as p15A may result in at least 10-time increased plasmid yields isolated from E.
  • coli bacteria compared to that obtained using a BAC.
  • the increased stability and efficiency enables high-throughput work which is in sharp contrast to conventional methods used for adenovirus genome cloning.
  • the plasmid of step b) is linearized prior to electroporating it into a host cell in which homologous recombination occurs.
  • the plasmid of step b) is linearized in vivo, for example, using a rare site sequence-specific cutting enzyme, for example as described in reference 20.
  • any suitable 5' to 3' exonuclease and annealing protein may be used.
  • the 5' to 3' exonuclease is full-length RecE (SEQ ID NO:1412) as described in reference 20 (incorporated herein by reference), or a protein with at least 70% sequence identity to the full-length form (preferably at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9%) which retains the 5' to 3' exonuclease activity.
  • the annealing protein is preferably RecT.
  • the method comprises co-electroporating the first linear nucleic acid molecule and the linearized plasmid into a host cell that expresses full length RecE and RecT.
  • the method is carried out in a host cell in which full-length RecE is expressed under the control of an inducible promoter.
  • the host cell is an E. coli cell, for example, E. coli strain GBRed. Examples of suitable host cells are well known in the art, and are described in detail in reference 20..
  • the host cell expresses RecA and/or Red gamma.
  • a step of sequencing is carried out to determine the sequence of the adenovirus.
  • the method further comprises checking the integrity of the cloned adenoviral genome, for example, using diagnostic restriction enzyme digest and/or next generation sequencing.
  • the invention provides a cloning method as described herein to clone a viral genome sequence, preferably, a double stranded DNA viral genome sequence.
  • the virus is not an adenovirus.
  • the virus has a genome which is less than 70kb in length, e.g. less than 65kb, 60kb, 55kb, 50kb, 45kb, 40kb or 35kb in length.
  • the virus has a genome which is more than 10kb in length, for example, more than 12kb, 15kb, 20kb, 25kb or 30kb in length.
  • the virus is between 10-70kb in length, e.g.
  • the invention further provides a plasmid vector comprising a full length adenoviral genome sequence.
  • the plasmid has been obtained by or is obtainable by a method as described herein. Accordingly, the description provided of the adenoviral sequences and the plasmid vectors in the methodology described herein can be extrapolated to this aspect of the invention which is the plasmid vectors comprising the cloned adenoviral sequences.
  • the plasmid comprises a full length adenoviral genome sequence as described herein.
  • the plasmid comprises the full length adenoviral genome sequence contained within any one of SEQ ID NOs 1 -32 or 141 1 , or a sequence at least 70% identical thereto (preferably at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9%) .
  • the plasmid comprises the genome sequence contained within any one of SEQ ID NOs: 1 -3, 5-8, 10-12, 14-15, 17-25, 27-32 and 141 1 , or a sequence at least 70% identical thereto (preferably at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9%).
  • the plasmid comprises an adenoviral genome that has not previously been sequenced.
  • the plasmid which contains the adenoviral sequence is a medium copy plasmid which comprises an origin of replication and a selectable marker such as an antibiotic resistance gene.
  • the plasmid comprises the p15A origin.
  • the plasmid is a medium copy plasmid which comprises an origin of replication, a selection marker and a full length adenoviral genome sequence, wherein the plasmid additionally comprises one or more restriction sites immediately upstream and immediately downstream of the adenoviral genome sequence, such that the adenoviral genome vector can be released from the plasmid vector.
  • the plasmid comprises a full length viral genome sequence, which in some embodiments is not an adenoviral sequence.
  • the full length viral genome sequence may be from polyomaviruses or papillomaviruses.
  • the invention further provides a library of cloned adenoviral genomes.
  • the adenoviral genomes are full length adenoviral genomes.
  • the invention provides a library of two or more (e.g. 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 or more) plasmid vectors each comprising a full length adenoviral genome sequence.
  • the two or more plasmid vectors have been obtained by or are obtainable by a cloning method as described herein.
  • the library comprises sequences of at least two (e.g. 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20) different adenoviruses.
  • there is a provided a library comprising two or more of the plasmid vectors comprising a full length adenoviral genome sequence that are described herein.
  • the cloned adenoviruses in the library are tagged with a reporter gene.
  • a plasmid that is suitable for use in step b) of the cloning method.
  • the plasmid may be provided in circular form or in linearized form.
  • the invention provides a plasmid comprising an origin of replication, a selection marker, and two regions of homology with the ITR regions of an adenoviral genome sequence, wherein one region has homology to the 5'ITR and a second region has homology to the 3'ITR.
  • the descriptions of the plasmids for use in the cloning method of the invention can be extrapolated to this aspect of the invention.
  • the plasmid is a medium copy plasmid such as a p15A, pBR322, pR6K, pRK2, pBBR1 or an Inc-based plasmid.
  • the plasmid of this aspect of the invention will contain less than 1000 nt of adenoviral sequence, for example, less than 900, 800, 700, 600, 500, 400, 300, 250, 200, 150, 100, 50, 25, 15 or 10 nt.
  • the invention further provides a method for determining whether an adenovirus is present in a sample, comprising contacting the sample, or genomic DNA derived from the sample, with a linearized plasmid as described herein which comprises at least two regions of sequence homology with an adenoviral sequence in the presence of a 5' to 3' exonuclease and an annealing protein such that if an adenoviral genome sequence is present in the sample, it will recombine with the linear plasmid to form a circular plasmid containing an adenoviral sequence, and further comprising a step of determining whether a circular plasmid containing an adenoviral sequence has been formed.
  • such a method may be carried out using a method for cloning an adenoviral sequence as described herein.
  • the linearized plasmid shares a region of sequence homology with the 5' ITR of an adenoviral sequence and shares a region of sequence homology with the 3' ITR of the adenoviral sequence.
  • the method further comprises the step of determining the identity of the cloned adenoviral sequence, for example, by sequencing all or part of the cloned adenoviral sequence and/or analysing the cloned adenoviral sequence using restriction enzyme digestion.
  • the method comprises contacting a sample with a library of linearized plasmids comprising homology regions which have been designed to target different adenoviruses. In some embodiments, the method comprises contacting the sample with all the members of the library simultaneously. In some embodiments, the method comprises carrying out multiple experiments using individual members of the library.
  • the invention further provides a library of plasmids that are suitable for use in step b) of a method for cloning as described herein, wherein the individual members of the library share regions of sequence homology with the 5' ITR and 3' ITR of different adenoviruses.
  • the library has at least 2, 3, 4, 5, 10, 15, 20, 25 or 30 members.
  • the invention also provides an adenoviral vector that has been released in linear form from the circular plasmid containing the adenoviral genome sequence, e.g. by restriction digestion, as described herein.
  • the method of generating a vector generally uses linear to circular homologous recombination (LCHR) to delete one or more regions of the adenoviral genome as discussed above. Accordingly, in one embodiment, the invention provides a method of generating an adenoviral vector or helper vector, comprising:
  • the first circular nucleic acid molecule described in step a) has been generated using the LLHR direct cloning method described above. Accordingly, the description of the adenoviral sequence and the plasmid vector described for the cloning method can be extrapolated to this aspect of the invention.
  • a plasmid vector as described herein which comprises the modified adenoviral genome sequence obtained by or obtainable by this method of the invention.
  • the plasmid vector comprises the sequence of an adenoviral vector as described herein.
  • the adenoviral vector can be released in linear form from the first circular nucleic acid molecule e.g. by restriction digestion.
  • the circular nucleic acid molecule will comprise restriction sites both 5' and 3' of the adenoviral sequence.
  • the linearized plasmid used in the cloning method comprises restriction sites 5' and 3' of the two regions of sequence homology (i.e. so that the resulting circular nucleic acid molecule comprising the cloned adenoviral sequence comprises the restriction sites 5' and 3' of the adenoviral sequence).
  • the released adenoviral vector does not comprise any plasmid sequence.
  • the released adenoviral vector comprises less than 1000 nt plasmid sequence at the 5' and/or 3' end, for example, less than 900, 800, 700, 600, 500, 400, 300, 250, 200, 150, 100, 50, 25, 15 or 10 nt.
  • Suitable deletions are discussed above in relation to the vectors (for example, the E1 region and/or the E3 region, and/or other early gene regions).
  • all coding sequences are deleted.
  • non-essential sequences e.g. E3 sequences
  • mutations may be made using the second linear nucleic acid, for example in the E1 and/or E2 region.
  • Insertions may also be made, for example to insert a transgene or other non- adenoviral DNA, for example as discussed above.
  • a transgene or other non- adenoviral DNA for example as discussed above.
  • at least some non- essential regions of the adenoviral genome are deleted to create coding capacity for the inserted DNA.
  • the linear nucleic acid may be less than 180 nucleotides in length (for example, 150 nucleotides or less, 130 nucleotides or less, 1 10 nucleotides or less, 100 nucleotides or less, 80 nucleotides or less, 60 nucleotides or less or 55 nucleotides or less).
  • the second linear nucleic acid molecule shares at least two regions of sequence homology with the first nucleic acid molecule, where the regions of sequence homology have been designed to remove the intervening sequence that is present in the adenoviral sequence.
  • the sequence homology may be to either side of the E3 region to delete the entire E3 region.
  • the second nucleic acid molecule may be longer and comprise heterologous (non- adenoviral) DNA e.g. comprising one or more transgenes, between two regions of homology ("homology arms").
  • heterologous (non- adenoviral) DNA e.g. comprising one or more transgenes, between two regions of homology ("homology arms").
  • homology arms two regions of homology
  • Such methods are usually carried out in conjunction with a method of inserting one or more transgenes into a vector of the invention, as described below.
  • the first circular nucleic acid molecule may be e.g. a bacterial artificial chromosome (BAC), a p15A origin-based vector, a pBR322 origin-based vector, a fosmid, a pUC origin-based vector or a ColE1 origin-based vector.
  • BAC bacterial artificial chromosome
  • medium copy plasmids are preferred, for example, p15A, pBR322, pR6K, pRK2, pBBR1 and Inc-based plasmids, in particular p15A origin-based vectors.
  • Suitable 5' to 3' exonucleases include RecE 20 and Red alpha 36 . These exonucleases are used in conjunction with the annealing proteins RecT and Red beta, respectively.
  • the RecE may be either full-length (SEQ ID NO:1412) or a truncated form (e.g. RecE588 or RecE602), as described in reference 20 (incorporated herein by reference), or a protein with at least 70% sequence identity to the full-length or truncated form (preferably at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9%).
  • the Red alpha/Red beta system is preferred. If RecE is used, truncated RecE is preferred.
  • the first nucleic acid molecule described above which comprises the adenoviral sequence is linear (e.g. a linearized form of the circular nucleic acid molecule generated using the LLHR cloning method described herein, wherein the first nucleic acid is linearized either in vivo in the recombination-competent host cell, or is linearized in vitro) and the second nucleic acid is provided in circular form.
  • LCHR linear to circular homologous recombination
  • the method of cloning using LLHR and the method of deleting one or more regions of the adenoviral genome using LCHR, as described above, are carried out in the same host cell.
  • the host cell expresses full length RecE under the control of an inducible promoter and either truncated RecE and/or Red alpha under the control of one or more different inducible promoters.
  • the host cell also expresses the corresponding annealing proteins RecT and Red beta, respectively.
  • such a host cell allows independent temporal expression of the full length RecE/RecT system and the Red alpha/Red beta or truncated RecE/RecT system, such that the required recombination proteins can be activated at the point in time that they are required.
  • the invention also provides a method of generating a cell as defined above.
  • the method comprises transforming a cell with DNA encoding, and capable of expressing, at least an adenoviral E1 region selected from SEQ ID NOs:1 -3, 5-8, 10-12, 14-15, 17-25 or 27-32, or a sequence at least 70% identical thereto (preferably at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9%).
  • the DNA encoding the E1 region also encodes a selectable marker (for example neomycin, puromycin, hygromycin etc.)- The selectable marker allows detection of cells into which the DNA carrying the E1 region has integrated stably.
  • Means for expressing the E1 region and the selectable marker include e.g. an IRES or a promoter.
  • the method may also comprise transforming a cell with DNA encoding, and capable of expressing, Cre recombinase (Accession No. P06956) or Flp recombinase (Accession No. P03870). These cell lines are used when a helper vector is required.
  • the invention provides a method of inserting one or more transgenes into an adenoviral vector or helper vector according to the invention (including e.g. oncolytic or vaccine vectors). This method may be performed in conjunction with the method of generating an adenoviral vector as set out above.
  • the invention provides a method of inserting one or more transgenes into an adenoviral vector or helper vector, comprising:
  • the first circular nucleic acid molecule described in step a) has been generated using the LLHR direct cloning method described above. Accordingly, the description of the adenoviral sequence and the plasmid vector described for the cloning method can be extrapolated to this aspect of the invention.
  • a plasmid vector as described herein which comprises the modified adenoviral genome sequence obtained by or obtainable by this method of the invention.
  • the adenoviral vector can be released in linear form from the first circular nucleic acid molecule e.g. by restriction digestion.
  • the circular nucleic acid molecule will comprise restriction sites both 5' and 3' of the adenoviral sequence.
  • the method may also involve a deletion of part of the adenoviral sequence, as discussed above.
  • the second linear nucleic acid molecule may comprise the transgene(s) of interest, such that the transgene(s) is/are inserted into the first nucleic acid molecule in one step.
  • the method may be a two- or multi-step process in which the second linear nucleic acid molecule comprises e.g. a selectable marker, which is inserted into the first circular nucleic acid molecule in a first step.
  • a second step is then carried out comprising (a) to (c) above, but with a third linear nucleic acid molecule in place of the second linear nucleic acid molecule.
  • the third linear nucleic acid molecule carries the transgene(s) of interest, and comprises at least two regions of sequence homology with the intermediate circular nucleic acid molecule (which corresponds to the first circular nucleic acid molecule comprising sequence inserted from the second linear nucleic acid molecule).
  • the at least two homology regions on the second linear nucleic acid molecule are designed to target the transgene to the E3 region of the adenoviral genome sequence.
  • inserting the transgene simultaneously results in deletion of sequence within the adenoviral genome sequence, e.g. the E3 region.
  • the transgene is inserted into a region corresponding to a deleted sequence in the adenoviral sequence, e.g. the deleted E3 region.
  • the transgene is inserted in the adenoviral sequence without deleting any adenoviral sequence.
  • the use of a method of inserting a transgene allows tagged adenoviral vectors to be generated.
  • the second linear nucleic acid molecule is designed to comprise homology regions to a region that is conserved between adenoviral sequences, e.g. a conserved region in the E3 region, such that different adenoviral genomes can be tagged in a high- throughput manner using identical plasmid vectors.
  • Suitable 5' to 3' exonucleases and annealing proteins include those described above for methods of generating the adenoviral vectors of the invention.
  • the first nucleic acid molecule described above which comprises the adenoviral sequence is linear (e.g. a linearized form of the circular nucleic acid molecule generated using the LLHR cloning method described herein, wherein the first nucleic acid is linearized either in vivo in the recombination-competent host cell, or is linearized in vitro) and the second nucleic acid is provided in circularform.
  • linear e.g. a linearized form of the circular nucleic acid molecule generated using the LLHR cloning method described herein, wherein the first nucleic acid is linearized either in vivo in the recombination-competent host cell, or is linearized in vitro
  • the second nucleic acid is provided in circularform.
  • the adenoviral vector can be released in linear form from a circular nucleic acid molecule as described above, and the DNA vector purified using standard procedures.
  • the linear DNA can be transfected into target cells for vector amplification. If the vector is replication-deficient, the cell line will be a "producer cell line" as described above, which complements for one or more essential genes missing from the adenoviral vector. If the vector is helper-dependent, then the helper vector is also transfected into the producer cell line.
  • Packaged vectors or oncolytic viruses can be obtained from the cells, for example by cell lysis and particle purification using standard procedures. Helper viruses can be separated from packaged high-capacity vectors, for example by ultracentrifugation on cesium chloride density gradients and/or anion exchange and size exclusion chromatography.
  • adenoviral library disclosed herein can also be used to screen for potential new drug targets for anti-adenoviral therapeutic strategies.
  • adenoviral genome sequences comprising reporter genes are constructed, based on the adenoviral library disclosed herein.
  • the invention provides an adenoviral sequence selected from SEQ ID NOs:1 -3, 5-12, 14-15 and 17-32, comprising one or more reporter genes and means for their expression, replacing part or all of the E3 region.
  • Suitable reporter genes include a gene encoding a fluorescent protein, for example green fluorescent protein (GFP), and/or a luciferase gene. Multiple reporter genes can be inserted so that different assays can be conducted. These reporter genes thereby allow the identification of the tropism of the adenovirus as they can be used to establish the level of infectivity of that adenovirus in cell lines derived from different tissues. Vectors comprising such sequences are also provided.
  • the vector carrying the above sequence is a medium copy plasmid, for example, a p15A, pBR322, pR6K, pRK2, pBBR1 or an Inc-based plasmid. Plasmids with a p15A origin are particularly preferred.
  • the invention provides a method of screening for potential anti-adenoviral drugs, comprising: a) infecting a cell with a vector comprising one or more reporter genes and means for their expression, as described above, in the presence and in the absence of a drug of interest;
  • the relative expression levels of the reporter gene product(s) in the presence versus the absence of the drug give an indication of whether the drug reduces adenovirus infectivity (i.e. has anti-adenoviral activity). If the expression level is reduced in the presence of the drug, relative to the absence of the drug, it indicates lower infectivity in the presence of the drug, and therefore likely anti-adenoviral activity of the tested drug.
  • the above method can be used for high-throughput drug screening.
  • the adenoviral sequence is not a sequence derived from at least one of (e.g. of 1 , 2, 3, 4 or all 5 of) the adenoviruses selected from the group consisting of B3, B1 1 , B35, C5 and D26.
  • the adenoviral sequence is not a sequence derived from at least one of (e.g. of 1 , 2 or all 3 of) the adenoviruses selected from the group consisting of B1 1 , B35 and C5.
  • the adenoviral sequence is not a sequence derived from at least one of (e.g.
  • the adenoviral sequence is not a sequence derived from the C5 adenovirus.
  • the invention does extend to adenoviral sequences derived from at least one of (e.g. of 1 , 2, 3, 4 or all 5 of) the adenoviruses selected from the group consisting of B3, B1 1 , B35, C5 and D26.
  • FIG. 1 Schematic outline of wild-type adenovirus amplification and viral genome isolation a) Wild-type human adenoviruses from clinical isolation were first pre-amplified in individual permissive cell lines (50-80% confluence, 2% FBS) using repeated infection circles to achieve 90% cytopathic effect (CPE). Then each virus was amplified in a large scale manner in 10-20 15 cm tissue culture dishes. Crude cell lysates were used to purify viruses by CsCI gradients, followed by viral genome isolation and sequence verification.
  • CPE cytopathic effect
  • the shuttle vector p15A-cm-adHA was constructed by co-electroporation of four DNA fragments sharing terminal homologous arms (HAs) into the RecET expressing E. coli strain GBred-gyrA462, which has an R462C mutation in the GyrA subunit of DNA Gyrase that confers resistance to CcdB expression.
  • the final vector p15A-cm-AdV was generated via a second LLHR step in RecET expressing E. coli strain GBred by co-electroporation of the linearised shuttle vector and the linear double-stranded adenoviral DNA (linear-dsDNA). Ndel and BamHI restriction digestion was used to linearize the circle plasmids.
  • c) Recombineering efficiencies of viral genome cloning using various amounts of viral genomic DNA (0 to 1 ⁇ g) and 1 ⁇ g of the linearized shuttle vector. Error bars, s.d.; n 3.
  • the vector backbone p15A-cm was generated by a single PCR from a modified plasmid p15A-cm-MCs2.0. -50 bp homology arms (HAs) were incorporated into individual Ad genomes via primer design.
  • Y-axis indicates viral genome copy numbers isolated from cell/virus lysates collected after each passage.
  • X-axis is the passage number after transfection.
  • dd completed exposed adenoviral genome released by double-digest
  • sc linearized adenoviral genome released by single-cutter
  • p circular plasmid. Amp, ampicillin; cm, chloramphenicol; ccdB, counter-selection marker.
  • Figure 4 Recombineering toolkit for Ad genome tagging including plasmid maps and sequences of pR6K-spect-adapter and pR6K-GLN
  • pR6K-spect-adapter serves as a PCR template to amplify selection marker spectinomycin adenyltransferase (spect), which is flanked by the same homologous arm (HAR and HAL) as the reporter cassette GLN (shown in b).
  • EcoRI restriction enzyme digest releases the PCR template.
  • the R6K backbone is used to avoid plasmid contamination.
  • pR6K-GLN provides the reporter gene cassette GLN which is released by EcoRI restriction enzyme digest. £. co// strain GB05-Red harbouring an arabinose inducible gbaA operon (redy, red3, reda and recA) at the ybcC locus2 mediates highly efficient LCHR.
  • E. coli strain GBred-gyrA462 is generated from GB05-Red with the Arg462-coding codon CGT been changed into Cys-coding codon TGC, allowing resistance to CcdB expression 37 . All plasmid maps used in this study are created with SnapGene software.
  • Figure 5 Summary of the complete pipeline to study natural Ad diversity and to generate an engineered Ad library including tagging of viral genomes
  • the process begins with wild-type adenovirus amplification in respective permissive cell lines (e.g. HeLa, HEK, A549).
  • permissive cell lines e.g. HeLa, HEK, A549
  • the adenovirus genomic DNA is isolated and verified by sequencing and restriction enzyme digest.
  • the shuttle vector p15A-cm-adHA is computationally designed, and constructed by co-electroporation of four DNA fragments containing homologous arms (HA) to each other into the RecET expressed E. coli strain, where LLHR takes place.
  • the adenoviral genome is incorporated into the linearised shuttle vector containing HA to each ITR end via LLHR.
  • Sequence-verified plasmids harbouring adenoviral genomes are collected together building up an engineered adenoviral library.
  • Marker gene GFP/LUC tagging was mediated by linear-circular homologous recombination (LCHR).
  • the E3 region was first deleted by integration of the ccdB-Amp cassette, which was then replaced by a P2A peptide-mediated bicistronic-expression cassette expressing a Turbo Green fluorescent protein and a NanoLuc luciferase (tGFP-Nluc) to generate p15A-cm-AdV-tGFP-Nluc.
  • the tagged adenovirus AdV-delE3-tGFP-Nluc can be reconstituted in its permissive cell line and further evaluated in vivo.
  • Figure 11 - HAdV17 has tropism for endothelial cells in vitro
  • B Growth curve comparison between wild type HAdV17 and HAdV5.
  • HEK293, A549, Hela and EA.hy926 were seeded in 24 well plates the day before infection.
  • MOI multiplicity of infection
  • Cells were harvested at various time points (2, 10, 24, 48, 72 hours), and quantitative PCR was performed after cellular DNA isolation to detect assay for virus replication.
  • C Virus internalization analysis by quantitative PCR.
  • FIG 12 Transduction of primary human umbilical vein cells (HUVEC)
  • HUVEC primary human umbilical vein cells
  • Primary HUVECs were transduced with HAdV5GFP and HAdV17GFP at various multiplicities of infection (0.1 , 1 , 10 or 100 per cell) for 2 hours.
  • A GFP-positive cell numbers and
  • B mean fluorescent intensity were analysed 24h postinfection by FACS. Uninfected cells (negative controls) were used to set the background gate at approximately 1 %.
  • C Histograms show the surface markers hCAR on HEK293, HeLa, EA.hy926 and HUVEC by flow cytometry.
  • D Quantitation of mean fluorescent intensity of CAR expression on cell surfaces.
  • FIG. 1 Schematic representation of chimeric fiber proteins incorporated into HAdV5 capsid and structure of chimeric fiber genes (knob, shaft and tail). White depicts the fiber derived from HAdV5GFP and black depicts the fiber derived from HAdV17GFP.
  • HAdV5GFP/17knob contained the shaft and tail from HAdV5 and knob from HAdV17.
  • HAdV5GFP/17 fiber contained the tail from HAdV5 and both shaft and knob from HAdV17.
  • B HEK293 and EA.hy926 cells were seeded in 24 well plates the day before infection.
  • Viral genomes were detected by real-time quantitative PCR in various organs (liver, heart, lung, artery, kidney, pancreas, spleen, intestine and brain ) harvested 72hrs after systemic administration of 2x10 9 transducing units per mouse of HAdV17GFP into both CD46 transgenic mice and wild-type mice.
  • the top panel shows colocalisation of viral transgene (GFP) expression (green) with endothelial markers (CD31 , red) from CD46 transgenic mice injected with HAdV17GFP.
  • GFP viral transgene
  • CD31 endothelial markers
  • Single stained and merged images at 20X magnification are presented.
  • the scale bar of images is ⁇ ⁇ .
  • the 4 th panel from the top is from wild type mice injected with HAdV17GFP.
  • the 5 th panel from the top is from wild type mice injected with HAdV5GFP.
  • PBS treated transgenic mice (3 rd panel from the top) and PBS treated wild type mice (6 th panel from the top) are controls.
  • the 2 nd panel from the top is from CD46 transgenic mice injected with HAdV17GFP without CD31 primary antibody treatment.
  • the 7 th and 8 th panels from the top are views at a higher magnification (60x) of the first panel. Images are representative of multiple fields of view. The scale bar of images is 25 ⁇ .
  • A Reciprocal dilution of dog serum, immunised with HAdV-5, was incubated with HAdV17GFP and HAdV5GFP. The serum-virus mixture was used to infect HEK293 cells and 24 hours postinfection, GFP expression levels were determined.
  • B Preexisting immunity to HAdV17 in patients. Transduction assays were carried out in the presence of serum samples from 19 patients. Samples were considered neutralising if greater than 90% reduction in transduction (below 10% residual transduction) was seen in comparison to a no-serum control.
  • FIG. 17 Schematic structure of different virus vectors used in Example 3.
  • FIG. 1 Diagram of ccdB recombineering to construct first generation p15a-HAdV17GFP.
  • FIG. 2 Schematic structure of pseudotyping HAdV5GFP with knob or fiber from HAdV17.
  • Figure 18 Generating stable complementing cell lines based on HEK293 and A549 cells using the plasmid pIRES-neo
  • E1 cassette from HAdV17 (2808bp) was amplified by PCR and ligated into multi cloning site of plRESneo3 (clontech) to construct the vector pCMV-HAdV17E1 -IRES-neo.
  • B Methylene blue staining was performed to mark the positive cell clones.
  • C PCR and RT-PCR were performed to analyse each cell clone. Genomic DNA was isolated from each cell clone and eluted in dhbO. Total RNA was isolated and resuspended in RNase-free H2O. Reverse transcription was performed, and 5 ⁇ of the cDNA was used for PCR. A negative control without reverse
  • Figure 19 Histograms show the surface markers of hCAR and CD46 expression level in various cell lines by flow cytometry
  • 0.5x10 6 cells (HEK293, A549, HeLa, EA.hy926, MMDH3 and HCT1 16) were counted and washed with PBS supplemented with 1 % BSA, centrifuged (1500 g, 3 min), and resuspended in 100 ⁇ PBS/BSA and 2.5 ⁇ anti-hCAR antibody (Santa Cruz, sc-56892) following an incubation step at 4°C for 1 hour.
  • FIG. 20 High-throughput screening (HTS) of the reporter-tagged human adenovirus library in a panel of human tumour cells
  • adenovirus type number Transgene expression efficiency of different adenovirus types was tested in a panel of disease-specific cell lines. Levels were compared to the commonly used adenovirus type 5 (Ad5) and indicated as fold change. Luciferase expression was measured by addition of
  • FIG. 21 High-throughput screening (HTS) to identify virus candidates with high oncolytic potency in osteosarcoma cells
  • (B) Virus internalization efficiency in three osteosarcoma cell lines. Cells were infected with individual viruses at 2,000 vp/cell for three hours to determine viral genome copy numbers (VCN), which were quantified by qPCR and expressed as VCN per 10 ng total DNA. Error bars represent mean ⁇ SD. n 3 per group. Data were analysed by two-tailed unpaired t-test. P-values for analysed virus types compared to Ad5 were > 0.05 if not otherwise stated. * , significant (p ⁇ 0.05).
  • FIG. 22 High-throughput screening (HTS) to identify virus candidates with high oncolytic potency
  • Oncolysis assay performed in A549 cells as oncolytic assay control. Crystal violet staining of viable cells was used to evaluate oncolytic activity 7 days after infection.
  • Ad5 Ad21 and Ad37 showed high luciferase (26 hs p.i.) and GFP expression (2 ds p.i.), albeit without being significant. All three viruses reached about the same dimension of efficiency.
  • PCR fragments with homology arms (HA) for directed cloning contained the 5' and 3' ITR sequences, the previously published selection marker ccdBI O and ampicillin for advanced positive and counter selection and the plasmid backbone with a p15A origin of replication and the chloramphenicol resistance gene ( Figure 1 ).
  • Different ratios of PCR products were tested, and after homologous recombination (HR) in a RecET expressing £. coli strain this resulted into the novel medium copy plasmid p15A-cm-adHA. Equal amounts of all 4 PCR fragments resulted in highest cloning efficiency ( Figure 2b).
  • FIG. 2c shows recombineering efficiencies of direct viral genome cloning using various amounts of viral DNA (0 to 1 ⁇ g) and 1 ⁇ g of the linearised shuttle vector.
  • the plasmid backbone for direct cloning of large dsDNA viruses containing the p15A origin of replication results in significantly increased cloning efficiencies and is easier to handle compared to commonly-used bacterial artificial chromosomes (BAC). Since numerous viral genomes show high sequence homologies in their ITR sequences, viral genomes could be cloned simultaneously using the same shuttle vector p15A-cm-adHA containing the same HA. Only 50 bp HA are required, enabling fast and reliable direct HTC. The same strategy was used for Ad from species D, B2 and C.
  • Integrity of all cloned Ad genomes was checked by diagnostic restriction enzyme digests and compared to originally isolated Ad genomes from virions ( Figure 2). NGS was used to determine exact sequences of all Ad containing plasmids. Extensive rescue experiments were performed and the strategy optimised by testing different molecular forms (precise excision of the Ad genome, linearised Ad containing plasmid and circular Ad genome containing plasmid) ( Figure 3). After introduction of viral DNA into Ad permissive cell lines, viral replication was monitored by quantitative PCR (qPCR) over more than 5 serial passaging steps and the precise excision of the Ad DNA molecule from the plasmid was most sufficient in rescuing Ad. This strategy was then applied to all cloned human Ad.
  • qPCR quantitative PCR
  • LCHR was applied for marker insertion into the early gene E3 region of the cloned Ad genomes of the library.
  • spectomycin acetyltransferase was inserted via HR in E. coli strain GB05-Red into the adenoviral genome, followed by GLN cloning.
  • Tagging of Ad enabled in vitro and in vivo characterisation of chosen Ad types.
  • the in vivo tropism was analysed by systemically injected tagged HAdV-B3, HAdV-B16, HAdV-B50, HAdV-C5, and HAdV-E4 into C57BI/6 mice.
  • viruses also showed a distinct biodistribution as detected by transgene expression levels and viral genome level.
  • a summary of the complete pipeline to study natural Ad diversity and to generate an engineered Ad library including tagging of viral genomes is shown in Figure 5.
  • DMEM Dulbecco's Modified Eagle's Medium
  • PAN-BIOTECH 100 U ml-1 penicillin
  • PAN BIOTECH 100 g ml-1 streptomycin
  • Non-Essential Amino Acid (NEAA) was added.
  • NEAA Non-Essential Amino Acid
  • FBS 100 U ml-1 penicillin and 100 ⁇ g ml-1 streptomycin was used.
  • Wild type adenoviruses - HAdV-C5 (ATCC® VR5TM) strain and HAdV-F41 (ATCC® VR930TM) was obtained from the American Type Culture Collection (ATCC).
  • ATCC American Type Culture Collection
  • HAdV-A12, -A18.-A31 , -B3, -B16, B21 , -B1 1 , -B14, -B35, -C6, -D9, -D10, -D13, - D17, -D20, -D24, -D25, -D26, -D27, -D33, -D37, -D69 and -E4 were clinical isolates obtained from the diagnostic group of the Max von Pettenkofer-lnstitute (Department of Virology) at the Ludwig-Maximilians-University Kunststoff in Germany.
  • Ad amplification, purification and titration - WT human Ad from clinical isolates were first pre- amplified in individual permissive cell lines (50-80% confluence), with serial infection circles to achieve 90% cytopathic effect (CPE). Each virus was amplified to large scale in 10-20 15cm tissue culture dishes. For virus amplification DMEM supplemented with 2% FBS was used. Crude cell lysates were used to purify viruses by a CsCI gradient-based ultracentrifugation method (Beckman Coulter), followed by a desalting step based on disposable PD-10 desalting columns (GE Healthcare). The purified virus was aliquoted and stored at -80°C for further use. Ad particle concentrations were determined by measuring the optical density at 260nm and expressed as viral particles (VPs) per milliliter.
  • VPs viral particles
  • PCR - Homology arm (HA)-containing long primer-mediated PCR was performed with Phusion® High-Fidelity DNA Polymerase (New England Biolabs, Frankfurt, Germany) according to the manufacture's protocol. Notably, only the primer binding sequence (-20 bp) was used for calculating the annealing temperature.
  • OneTaq® 2X Master Mix was used according to the manufacture's standard protocol.
  • NGS and bioinformatics analyses For sequencing of plasmids, 200 ng purified DNA was subjected to standard lllumina DNA library preparation. In brief, DNA was enzymatically sheared (NEBnext dsDNA Fragmentase, New England Biolabs). After XP bead purification (Beckman Coulter), ends were polished and A-tailed and universal adapters were ligated (Ultra Directional DNA Library Prep Kit, New England Biolabs).
  • Adaptor-Oligo 1 5'- ACA-CTC-TTT-CCC-TAC-ACG-ACG-CTC-TTC-CGA-TCT- 3'
  • Adaptor-Oligo 2 5'-P-GAT-CGG- AAG-AGC-ACA-CGT-CTG-AAC-TCC-AGT-CAC-3'
  • adapters were depleted by XP bead purification (Beckman Coulter). Sample indexing was done in the following PCR enrichment (15 cycles).
  • CDS coding sequences
  • Sequence alignments between adenovirus sequence and GenBank reference were done with BLASTZ. As cut-off value, we used a minimum sequence identity of 99% which minimizes false-positive alignments but still allows for studying single nucleotide variants between adenovirus sequences and respective GenBank references.
  • ethanol precipitation was performed for DNA digested with Pmel/Sbfl and Pacl/Swal, and for l-Scel digested DNA a phenol-chloroform extraction followed by ethanol precipitation was conducted.
  • A549 cells were plated in 6-well plates and at 50-80% confluency 3 ⁇ g of digested viral DNA was transfected using Superfect transfection Reagent (Qiagen) according to the manufacturer's protocol. After 24-48 hrs, when the cells grew to up to >90% confluency, the medium was changed to 2% FBS-supplemented DMEM. The cells were maintained for up to two weeks, until cytopathic effect (CPE) was observed.
  • CPE cytopathic effect
  • the cell/virus lysate was collected and 1/2 or 1/3 of the lysate was used to infect a new well of A549 cells at a confluency of 90-95%.
  • the crude lysate was subjected to three freeze/cycles in liquid nitrogen and in a 37 °C water bath. A small aliquot of cells was collected for qPCR analysis.
  • Ad in vitro and in vivo - All reconstituted GLN-tagged viruses were confirmed by hexon-PCR of isolated adenoviral genomes.
  • Adenovirus particle concentrations were determined by measuring the optical density at 260 nm and expressed as viral particles (vps) per millilitre.
  • Nano-Glo Luciferase assay Individual tested cells were grown to confluence in 96-well tissue culture plate and infected with different viral partials (VPs) per cells. 26h after infection NLuc activity was measured with the Nano-Glo assay system (Promega), and luminescence was detected with a plate reader (Tecan).
  • VPs viral partials
  • Genome uptake measured by internalization assay - To quantify the cell entry efficiency, a defined number of Ad particles (vp) was used to infect pre-seeded tumor cells and incubated for 2 hours. Cell monolayers was digested and flushed off with trypsin, followed by extensive washing with PBS. Genomic DNA was extracted by incubation in TE buffer (10 mM Tris-HCI, 10 mM EDTA, pH 8.0) with 0.5% SDS and 0.5 mg/ml proteinase K. Subsequently a phenol-chloroform extraction and ethanol precipitation was performed. To monitor virus genome uptake efficiency, quantitative real-time PCR (qPCR) detecting the transgene (GLN gene cassette) was performed.
  • qPCR quantitative real-time PCR
  • Oncolytic assays with most promising Ad candidates - Oncolytic assay was performed in 24 well plates. A 10-fold dilution series of individual Ads was prepared freshly to infect pre-seeded cancer cells. Cytopathic effect (CPE) was checked daily until at least one of the viruses on one plate at the lowest dosage showed CPE or until maximal 14 days. The cells were first fixed with 3.7% formaldehyde then stained with crystal violet solution. Statistics - Statistical analyses were conducted with Microsoft Excel. Experimental differences were evaluated by a Student's one-tailed t-test assuming equal variance.
  • Genes were predicted using Gene Locator and Interpolated Markov ModelER (Glimmer) 38 .
  • Glimmer Genes were predicted using Gene Locator and Interpolated Markov ModelER (Glimmer) 38 .
  • protein sequences of known genes of the respective reference from GenBank were aligned with exonerate 39 to the assembled genome sequence.
  • the coordinates of the best hits were then used to build a Glimmer model which was subsequently used for prediction of location and orientation of genes in the sequenced genome.
  • Shading of a gene reflects its maximum sequence divergence across all 28 viruses determined through an all-vs-all Blast analysis.
  • Example 3 cell tropism of human adenovirus D17
  • a new first generation adenovirus based on human adenovirus D17 was constructed and labelled with a green fluorescent protein (GFP) marker using the recombineering technology described in Example 1.
  • GFP green fluorescent protein
  • the early E1 gene was deleted in the HAdV17 vector, and a corresponding E1 -deleted, GFP-labeled HAdV5 vector was constructed for comparison.
  • Viruses were rescued in complementary E1 -expressing stable cell lines, and then screened against a panel of different cell lines by fluorescence activated cell sorting (FACS) analysis and quantitative PCR.
  • FACS fluorescence activated cell sorting
  • HAdV17 could utilize both CD46 (a membrane cofactor protein which is expressed on all nucleated cells) and CAR (coxsackievirus and adenovirus receptor) as cell attachment receptors.
  • CD46 a membrane cofactor protein which is expressed on all nucleated cells
  • CAR coxsackievirus and adenovirus receptor
  • the endothelial cell tropism was CD46-dependent and could be blocked by the CD46 blocking reagent Augmab.
  • In vivo biodistribution analyses were performed after intravenous injection of recombinant viruses into both normal and CD46-transgenic mice. These studies showed significantly increased vector genome copies (VCN) in various organs of CD46-transgenic mice compared to normal mice, indicating the involvement of CD46 as a receptor.
  • Neutralising antibody assays revealed that there was less seroprevalence with HAdV17 compared to HAdV5 in humans.
  • HAdV17-based vectors which can use both hCAR and CD46 as receptors and display an endothelial cell tropism, hold great promise for gene therapy in endothelial disease.
  • Example 4 delivery of all components of the CRISPR/Cas9 system using high-capacity adenoviral vectors
  • a new CRISPR/Cas9 shuttle plasmid toolbox was generated, containing the Cas9 nuclease gene, either utilising a constitutive or an inducible promoter, and a gRNA expression unit.
  • the toolbox allows cloning or recombining of all CRISPR/Cas9 components into the HCAdV genome in one step.
  • DNA recombineering was used to introduce all CRISPR/Cas9 expression units into the HCAdV genome contained in the bacterial artificial chromosome pBHCA.
  • CRISPR-HCAdVs were produced using a shortened amplification and purification procedure.
  • the toolbox was used to produce several CRISPR-HCAdVs carrying single and multiplex gRNA units specific for different targets including hCCR5, hDMD, and HPV16- and HPV18-E6 genes, yielding sufficient titers within a short time.
  • T7E1 assays 41 were applied to prove CRISPR/Cas9- mediated cleavage of respective targets. Infection of cultured human cells with respective CRISPR- HCAdVs resulted in efficient site-specific gene editing.
  • this new platform enables customisation, cloning and production of CRISPR-HCAdV vectors for single or multiplex approaches within a short time. It simplifies the delivery of the CRISPR/Cas9 machinery by only using one single viral vector. Inducible Cas9 expression helps to avoid targeting of the genome of producer cell lines during vector production and may be beneficial for special approaches where constitutive expression is unwanted.
  • AdV oncolytic adenoviruses
  • CAR coxsackie- and adenovirus receptor
  • Oncolytic efficacy of the candidate virus can be augmented by expression of RNAi suppressor protein P19, as has been shown previously for hAdV-5 31 .
  • RNAi suppressor protein P19 RNAi suppressor protein P19
  • a novel hAdV-6-based, p19-containing oncolytic AdV was evaluated as a candidate for oncolytic applications in different tumour cell lines.
  • a P19-containing hAdV-6 based virus (hAdV-6FP19) was cloned by a novel seamless recombineering technique (see Example 1 ).
  • the P19 cDNA was fused via an internal ribosome entry site (IRES) to the late fiber gene.
  • IRS internal ribosome entry site
  • linearised viral DNA was transfected into HEK 293 cells for virus reconstitution.
  • upscaling and virus purification using cesium chloride density gradient ultracentrifugation was performed. Rescue and amplification efficiencies were comparable to commonly used hAdV-5 based vectors.
  • ⁇ AdV-6FP19, hAdV-6 and hAdV-5 were infected with hAdV-6FP19, hAdV-6 and hAdV-5 at various multiplicities of infection (MOI). Two to three days after infection, cells were fixed and stained with methylene blue. Significantly higher cell lysis (up to 100-fold) was observd for hAdV-6FP19-infected cells as compared to hAdV-5 and 6 at identical MOIs.
  • hAdV6-based vectors hold great promise for oncolytic applications and their oncolytic effectiveness can be further improved by RNAi suppression.
  • Example 6 High throughput screening (HTS) of adenovirus library as a novel resource for disease-specific targeting
  • osteosarcoma derived cell line MG-63
  • Ad37 was identified as the most efficient Ad type, while other species B types (Ad16, 50 and 35) revealed improved efficiency compared to the commonly used Ad5 (Fig. 20).
  • Ad21 showed highest transduction efficiencies (Fig. 20). Therefore, Ad21 was further pursued as a potential oncolytic agent to treat osteosarcoma, because this type of cancer is the most frequent primary cancer of bone which predominantly occurring in the second decade of life.
  • osteosarcomas represent >10% of all solid cancers. Therefore, a panel of osteosarcoma cell lines with different grading related features, including Saos-2 and U-2 OS cells, was further examined.
  • Ad21 was identified as a promising alternative Ad type to transduce osteosarcoma cell lines, which was also confirmed by GFP also expressed form the tagged Ads ( Figure 21 b) and by virus internalization assays measuring uptake of virus genomes 3 hrs post-infection ( Figure 21 c).
  • the oncolytic potency of selected Ad types was analysed in all three osteosarcoma cells and it was found that Ad21 consistently resulted in efficient oncolysis of respective cell lines at different MOIs tested ( Figure 21 d).
  • Example 7 Protocol to isolate adenoviral genomic DNA for use in the cloning step
  • phase lock gel tube Phase Lock Gel Heavy 1 .5 ml
  • Ad26 Recombinant adenovirus serotype 26
  • Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against Ebolavirus challenge. J. Virol. 85, 4222-4233, (201 1 ).
  • RNAi suppressor P19 can be broadly exploited for enhanced adenovirus replication and microRNA knockdown experiments. Sci. rep. 3, 1363 (2013).
  • CD46 is a cellular receptor for group B adenoviruses. Nat. Med. 9, 1408-1412 (2003).

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des vecteurs adénoviraux, des cellules destinées à être utilisées dans la production de vecteurs adénoviraux, des procédés de production de vecteurs adénoviraux, et des utilisations thérapeutiques de vecteurs adénoviraux en thérapie génique, en thérapie antitumorale et comme vaccins.
EP17723271.7A 2016-04-06 2017-04-06 Vecteurs adénoviraux Ceased EP3440213A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP21202131.5A EP3998341A3 (fr) 2016-04-06 2017-04-06 Vecteurs adénoviraux

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201605903 2016-04-06
PCT/EP2017/058306 WO2017174753A1 (fr) 2016-04-06 2017-04-06 Vecteurs adénoviraux

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP21202131.5A Division EP3998341A3 (fr) 2016-04-06 2017-04-06 Vecteurs adénoviraux

Publications (1)

Publication Number Publication Date
EP3440213A1 true EP3440213A1 (fr) 2019-02-13

Family

ID=58707477

Family Applications (2)

Application Number Title Priority Date Filing Date
EP21202131.5A Pending EP3998341A3 (fr) 2016-04-06 2017-04-06 Vecteurs adénoviraux
EP17723271.7A Ceased EP3440213A1 (fr) 2016-04-06 2017-04-06 Vecteurs adénoviraux

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP21202131.5A Pending EP3998341A3 (fr) 2016-04-06 2017-04-06 Vecteurs adénoviraux

Country Status (4)

Country Link
US (2) US11866724B2 (fr)
EP (2) EP3998341A3 (fr)
CN (1) CN109715813A (fr)
WO (1) WO2017174753A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3906038A4 (fr) 2018-11-21 2022-06-01 Mayo Foundation for Medical Education and Research Adénovirus et méthodes d'utilisation d'adénovirus
JP7381604B2 (ja) 2019-04-29 2023-11-15 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 癌を治療するための多価ｐｄ－ｌ１結合化合物
CA3156471A1 (fr) * 2019-10-03 2021-04-08 Janssen Vaccines & Prevention B.V. Vecteurs d'adenovirus et leurs utilisations
CN114540413B (zh) * 2020-11-24 2023-10-13 中国人民解放军军事科学院军事医学研究院 Dna分子与重组病毒及它们的制备方法和用途
CN114645042A (zh) * 2020-12-18 2022-06-21 中国食品药品检定研究院 一种构建具有表达荧光素酶和红色荧光蛋白的重组巨噬细胞的转基因小鼠的方法
IL307604A (en) * 2021-04-15 2023-12-01 Ensoma Inc Adenoviral vectors for gene therapy
AU2022349649A1 (en) * 2021-09-23 2024-04-04 Sagittarius Bio, Inc. Adenoviruses and methods for using adenoviruses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140087A (en) * 1993-06-24 2000-10-31 Advec, Inc. Adenovirus vectors for gene therapy
US20010006629A1 (en) * 1993-10-25 2001-07-05 Richard J. Gregory Recombinant adenoviral vector and methods of use
US6642052B2 (en) * 1999-02-25 2003-11-04 National Research Council Of Canada Efficient generation of adenovirus-based libraries by positive selection of adenoviral recombinants through ectopic expression of the adenovirus protease
US6355412B1 (en) * 1999-07-09 2002-03-12 The European Molecular Biology Laboratory Methods and compositions for directed cloning and subcloning using homologous recombination
US6916635B2 (en) 2000-10-02 2005-07-12 The Research Foundation Of State University Of New York Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof
GB0803109D0 (en) 2008-02-20 2008-03-26 Gene Bridges Gmbh Method of nucleic acid recombination
CN101619324B (zh) * 2008-07-01 2013-06-26 中国疾病预防控制中心病毒病预防控制所 复制缺陷型重组腺病毒Ad41载体系统及其应用
GB201009732D0 (en) * 2010-06-10 2010-07-21 Gene Bridges Gmbh Direct cloning
JP5981916B2 (ja) * 2010-08-16 2016-09-07 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの構築方法

Also Published As

Publication number Publication date
US20190382793A1 (en) 2019-12-19
EP3998341A3 (fr) 2022-08-24
US11866724B2 (en) 2024-01-09
WO2017174753A1 (fr) 2017-10-12
US20240191255A1 (en) 2024-06-13
CN109715813A (zh) 2019-05-03
EP3998341A2 (fr) 2022-05-18

Similar Documents

Publication Publication Date Title
US20240191255A1 (en) Adenoviral Vectors
SM Wold et al. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy
CA2568995E (fr) Construction d'une recombinaison d'adenovirus oncolytique exprimant de facon specifique un facteur immunomodulateur gm-csf dans des cellules tumorales et utilisations correspondantes
Zhang et al. An engineered virus library as a resource for the spectrum-wide exploration of virus and vector diversity
JP5075839B2 (ja) 癌の処置のための腫瘍崩壊性アデノウイルス
JP6683847B2 (ja) 強力でバランスのとれた双方向性プロモーター
CA2930967C (fr) Adenovirus oncolytiques presentant une proportion augmentee de l'isoforme d'epissage 156r de la proteine e1 b
Rivera et al. Mode of transgene expression after fusion to early or late viral genes of a conditionally replicating adenovirus via an optimized internal ribosome entry site in vitro and in vivo
US10131921B2 (en) Single cycle replicating adenovirus vectors
JP2007527215A (ja) アデノウィルスｅ１ａ／ｅ１ｂ補完細胞株
US20060257370A1 (en) Adenoviral vectors for treating diseases
JP2008048621A (ja) キメラ型アデノウイルスとその作製方法並びにそれを用いた医薬
EP3305904B1 (fr) Promoteur dérivé de poxvirus, et vecteur le comprenant
Patel et al. Gene delivery using viral vectors
AU781775B2 (en) Adenoviral vectors for treating disease
Wen et al. Novel and efficient method for the reconstruction of adenoviruses through isothermal assembly and its potential applications
US20240301362A1 (en) Adenoviral serotype 35 helper vectors
Oualikene et al. Lack of evidence of phenotypic complementation of E1A/E1B-deleted adenovirus type 5 upon superinfection by wild-type virus in the cotton rat
Yu et al. A simplified system for generating recombinant E3-deleted canine adenovirus-2
Wu et al. Generation of a replication-deficient recombinant human adenovirus type 35 vector using bacteria-mediated homologous recombination
Dawson et al. Role of Homologous Recombination/Recombineering on Human Adenovirus Genome Engineering: Not the Only but the Most Competent Solution
CN113774031B (zh) 一种复制型人腺病毒及其应用
JP7046835B2 (ja) 強力でバランスのとれた双方向性プロモーター
Sajib Multilevel Targeting of Canine Adenovirus Type 2 (CAV2) to Expand Oncolytic Virotherapy in Canine Tumors
EP2020436A1 (fr) Procede de production de vecteurs adenovirus destines a la therapie genique et sequences d'adn utilisees a ces fins

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20181106

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200103

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20210813